2017N323364_01 CONFIDENTIA L
GlaxoSmithKline group of companies 207626
1TITLE PA GE
Protocol Title: A Phase IV, 12 week, randomised, double-blind, double-dummystudy to 
compare single inhaler triple therap y, fluticasone furoate/umeclidinium/vilanterol
(FF/UMEC/VI) ,with tiotropi[INVESTIGATOR_496855] f unction and sy mptomsin 
participants with chronic obstructive pulmonary  disease
Protocol Number : 207626/ 01
Short Title : A randomisedstudy, comparing FF/UMEC/VI  single inhaler triple therap y
versus tiotropi[INVESTIGATOR_496856] y in participants with chronic obstructive pulmonary  
disease
Compound Number: [COMPANY_004]573719+GW642444+GW685698 ([COMPANY_004]2834425 )
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_638764] Information can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s): IND number 114873, EudraCT Number
2017-001190-16
Approval Date : 17-JUL-[ADDRESS_638765]-2017
Amendment 1 17-July-2018
Overall Rationale for the Amendment :This amendment is required to update the QTc 
stoppi[INVESTIGATOR_496857].  I n 
addition, a section describing Smoking Cessation Counselling has been added as does a 
corresponding assessment at the end of study  (Visit 4).  Clarified that run-in treatment 
should be collected at Visit 2, study  treatment at Visit 3, and albuterol/salbutamol at Visit 
5.  Also, wording regarding suggest ed order for assessments and procedures has been 
added to the end of the Schedule of Activities section.  Removed reference to Fridericia 
formula in calculation of QTc.  Clarification regarding collecting the CAT assessment 
questionnaire prior to the SGRQ -C has also been provided along with clarification that 
vital signs should be collected before the ECG and prior to spi[INVESTIGATOR_038] .  Also added 
clarification that CAT and SGRQ-C will both be collected at Visit 3 to mirror the SoA.  
Corrected reporting time rega rding pregnancy .  Finally, added wording to Genetics 
Appendix 9 regarding withdraw process and sample destruction process. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
4Section # and 
NameDescription of Change Brief Rationale
Table of Contents Added Smoking Cessation 
Counselling S ection (9.10)Explained the reasoning for the 
Smoking Cessation Counselling 
and to clarify the visits when this 
counselling will be provided
Section 2
Schedule of 
Activities (SOA) Added Smoking Cessation 
Counselling to Visit 4
Added collecting run -in 
treatment at Visit 2
Added collecting stud y 
treatment at Visit 3
Added collecting 
albuterol/salbutamol at Visit 5 
Added wording regarding 
order for assessments and 
procedures (CAT, SGRQ -C, 
Vitals, ECG, Spi[INVESTIGATOR_038] , 
Clinical L ab Assessments)Clarified that Smoking Cessati on 
Counselling will also be collected 
at Visit 4
Clarified that run -in medication 
should be collected at Visit 2
Clarified that study  treatment 
should be collected at Visit 3
Clarified that rescue medication 
(albuterol/salbutamol) should be 
collected a t Visit 5
Clarified the requested order of 
assessments and procedures at 
visits (1 and 2 in particular) when 
a number of assessments and 
procedures are collected and 
performed
Section 6.2
Exclusion Criteria 
13Removed reference to 
Fridericia formula in 
calculation of QTcFridericia and Bazett formulas 
provide equal safet y in calculation 
of QTc and either may  be used if 
done consistently  throughout the 
study 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
5Section 8.1
QTc Stoppi[INVESTIGATOR_496858]:
an increase in QTc b y 
> 60 msec from 
baseline or 
development of a QTc 
> 530 msec (based on 
an average of 
triplicate ECGs)
NOTE:  These criteria should 
be based on the average of 
QTc value of triplicate ECGs.  
For example, if an ECG 
demonstrates a prolonged QT 
interval, two more ECGs w ill 
be obtained over a brief period 
and then the averaged QTc 
value of the three ECGs will 
be used to determine whether 
the patient should be 
discontinued from the studyAdapted the QTc stoppi[INVESTIGATOR_496859] 9.1.1
Spi[INVESTIGATOR_496860]:  If applicable, after 
completing the health 
outcomes assessments (CAT 
should be administered first 
followed b y SGRQ-C)CAT is a shorter assessment 
questionnaire to complete and the 
participant will alread y have 
experience completing this at 
Screening Visit [ADDRESS_638766] 
experience completing this at 
Screening Visit 1 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
6Section 9.2.9
PregnancyCorrected to match Appendix 
3:  If a pregnancy  is reported, 
the Investigator should inform 
[COMPANY_004] within 24 hours of 
learning of the pregnancy  and 
should follow the procedures 
outlined in Appendix 3Clarified that the reporting period 
for pregnancy  should be within 24 
hours of learning of the pregnancy  
and not 2 weeks as previously  
written
Section 9.4.3
ElectrocardiogramsCorrected:  A single 12 -lead 
ECG and rh ythm strip will be 
recorded after measurement of 
vital signs and prior to 
spi[INVESTIGATOR_496861] 9.10
Smoking Cessation 
CounsellingAdded Section 9.10
Smoking Cessation 
CounsellingExplained the reasoning and 
expectations for the Smoking 
Cessation Counselling
Appendix 9
GeneticsAdded wording for both 
withdraw process and 
destruction processExplained what should be done if 
a participant withdraws consent 
along with the destruction of 
samples after the storage period or 
on withdrawal of consent 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
7TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.SYNOPSIS ............................................................................................................. 10
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 17
3.INTRODUCTION .................................................................................................... 19
3.1. Study Rationale .......................................................................................... 19
3.2. Background ................................................................................................ 21
3.3. Bene fit/Risk Assessment ............................................................................ 23
3.3.1. Risk Assessment ......................................................................... 24
3.3.2. Risk Assessment for Tiotropi[INVESTIGATOR_195352] 18 mcg........................ 35
3.3.3. Benefit Assessment ..................................................................... 35
3.3.4. Overall Benefit:Risk Conclusion ................................................... 36
4.OBJECTIVES AND ENDPO INTS ........................................................................... 37
5.STUDY DESIGN .................................................................................................... 38
5.1. Overall Design ............................................................................................ 38
5.2. Number of Particip ants ............................................................................... 40
5.3. Participant and Study Completion ............................................................... 40
5.4. Scientific Rationale for Study Design .......................................................... 40
5.5. Dose Justification ........................................................................................ 41
6.STUDY POPUL ATION........................................................................................... 41
6.1. Inclusion Criteria ......................................................................................... 41
6.2. Exclusion Criteria ........................................................................................ 42
6.3. Randomisation Criteria ............................................................................... 47
6.4. Lifestyle Restrictions ................................................................................... 47
6.5. Pre-screening/Screening/Run -in/Randomisation Failures ........................... 47
7.TREATMENTS ....................................................................................................... 48
7.1. Treatment Groups and Duration ................................................................ .48
7.1.1. Medical Devices ........................................................................... 51
7.2. Dose Modification ....................................................................................... 51
7.3. Method of Treatment Assignment ............................................................... 51
7.4. Blinding ....................................................................................................... 51
7.5. Preparation/Handling/Storage/Accountability .............................................. 52
7.6. Treatment Compliance................................................................................ 53
7.7. Concomitant Therapy .................................................................................. 53
7.7.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 53
[IP_ADDRESS]. Permitted COPD Medica tions ..................................... 53
[IP_ADDRESS]. Permitted Non -COPD Medications ............................. 54
7.7.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ......................... 55
7.8. Treatment after the End of the Study .......................................................... 57
8.DISCONTINUATION CRIT ERIA ............................................................................. 57
8.1. Discontinuation of Study Treatment ............................................................ 57
8.1.1. Rechallenge ................................................................................. 59 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_638767] to Follow Up ........................................................................................ 59
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 60
9.1. Efficacy Assessments ................................................................................. 61
9.1.1. Spi[INVESTIGATOR_038] ................................................................................... 61
[IP_ADDRESS]. Reversibility ................................................................ [ADDRESS_638768] (CAT) .................................................... 63
9.1.4. COPD Exa cerbations ................................................................... 63
9.2. Adverse Events ........................................................................................... 63
9.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 64
9.2.2. Method of Detecting AEs and SAEs ............................................. 64
9.2.3. Follow -up of AEs and SAEs ......................................................... 64
9.2.4. Regulatory Reporting Requirements for SAEs ............................. 65
9.2.5. Cardiovascular and Death Events ................................................ 65
9.2.6. Disease -Related Outcomes –COPD exacerbations .................... 65
9.2.7. COPD exacerbations should not be recorded as an 
adverse event, unless they meet the definition of an SAE 
(Appendix 6).Pneumonia ............................................................. 66
9.2.8. Sentinel Eve nts............................................................................ 66
9.2.9. Pregnancy ................................................................................... 67
9.2.10. Medical Device Incidents (Including Malfunctions) ....................... 67
[IP_ADDRESS]. Time Period for Detecting Medical Device 
Incidents ..................................................................... 67
[IP_ADDRESS]. Follow -up of Medical Device Incidents ........................ 67
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents 
to Sponsor .................................................................. 68
[IP_ADDRESS]. Regulatory Reporting Requirements for 
Medical Devi ce Incidents ............................................ 68
9.3. Treatment of Overdose ............................................................................... 68
9.4. Safety Assessments ................................................................................... 68
9.4.1. Physical Examinations ................................................................ .69
9.4.2. Vital Signs .................................................................................... 69
9.4.3. Electrocardiograms ...................................................................... 69
9.4.4. Clinical Safety Laboratory Assessments ...................................... 69
9.5. Pharmacokinetics ....................................................................................... 70
9.6. Pharmacodynamics .................................................................................... 70
9.7. Genetics ..................................................................................................... 70
9.8. Biomarkers ................................................................................................ .70
9.9. Medical Resource Utilization and Health Economics .................................. 70
9.10. Smoking Cessation Counselling ................................................................ .70
10.STATISTICAL CONSIDER ATIONS ........................................................................ 71
10.1. Hypotheses ................................................................................................ .71
10.2. Sample Size Determination ........................................................................ 71
10.3. Populations for Analyses ............................................................................ 71
10.4. Statistical Analyses ..................................................................................... 72
10.4.1. Efficacy Analyses ......................................................................... 72
10.4.2. Safety Analyses ........................................................................... 73 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
910.4.3. Other Analyses ............................................................................ 73
10.4.4. Interim Analyses .......................................................................... 73
10.4.5. Exploratory Analyses ................................................................... 74
11.REFERENCES ....................................................................................................... 75
12.APPENDICES ........................................................................................................ 78
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 78
12.2. Appendix 2: Study Governance Considerations .......................................... 81
12.3. Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 85
12.4. Appendix 4: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 88
12.5. Appendix 5: COPD Exacerbation Identification, Categorization and 
Treatment Guidelines .................................................................................. 91
12.5.1. Guidelines for Identifying COPD Exacerbations ........................... 91
12.5.2. COPD Exacerbation Severity ....................................................... 92
12.5.3. Treatment of COPD Exacerbations .............................................. 92
12.5.4. Guidelines for Treatment with Corticosteroids .............................. 92
12.5.5. Guidelines for Treatment with Antibiotics ..................................... 93
12.5.6. Onset and Resolution of COPD Exacerbations ............................ 93
12.5.7. Guideline for assessing multiple mild exacerbations .................... 93
12.5.8 .Guideline for assessing exacerbations that increase in 
severity ........................................................................................ 93
12.6. Appendix 6: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 94
12.7. Appen dix 7: Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ..................................... 100
12.8. Appendix 8: Clinical Laboratory Tests ....................................................... 102
12.9. Appendix 9: Genetics ................................................................................ 104
12.10. Appendix 10: Country -specific requirements ............................................. 105
12.11. Appendix 11: Protocol Amendment History ............................................... 106 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
101. SYNOPSIS
Protocol Title: A Phase IV, 12 week, randomised , double-blind, double dummy study to 
compare single inhaler triple therap y, fluticasone furoate/umeclidinium/vilanterol
(FF/UMEC/VI) ,with tiotropi[INVESTIGATOR_496862]:A randomisedstudy, comparing FF/UMEC/VI  single inhaler triple therap y
versus tiotropi[INVESTIGATOR_496856] y in participants with chronic obstructive pulmonary  
disease
Rationale:   Chronic obstructive pulmonary  disease (COPD)guidelines advocate the use 
of long-acting muscarinic receptor antagonists (LAMA)added to the combination of an 
inhaled corticosteroid (ICS) plus a long-acting β 2-adrenergic receptor agonists (LABA) as 
second line therap y for the most advanced patients with significant s ymptoms and a high 
risk of exacerbations. Regular treatment with ICS -containing regimens has been reported 
to improve respi[INVESTIGATOR_23908], lung function, health related quality of life (HRQoL) 
and reduce the frequency ofCOPD exacerbations in patients with a forced expi[INVESTIGATOR_496863] 1 second ( FEV1) <60% predicted .
Population based studies of COPD treatment patterns demonstrate that ‘open’triple 
therapy (use of ICS/LAMA/L ABA delivered via multiple inhalers) is already  widely used 
in the real -life management of COPD. In 2011, 26 % of patients in the [LOCATION_002] ( US)
who were taking controller medicines for the treatment of COPD were taking an ‘open’
triple therap y, typi[INVESTIGATOR_496864]/salmeterol (ICS/LABA) to 
tiotropi[INVESTIGATOR_1890] (L AMA) or vice versa A s tudy in the [LOCATION_008] ( [LOCATION_006])Clinical Practice 
Research Database (CPRD) revealed that over a two -year period of time, 35 % of COPD 
patients initially  prescribed a LAMA and 39 % initially  prescribed an ICS/LABA stepped 
up to an ‘open’triple therapy  regimen. In the four -year long-term safet y study conducted 
with tiotropi[INVESTIGATOR_1890], 46 % of patients were receiving a concurrent fixed combination of 
ICS/LABA in addition to tiotropi[INVESTIGATOR_1890]. 
A number of studies have assessed the use of an ‘open’triple therapy  of fluticas one 
propi[INVESTIGATOR_16847]/salmeterol or budesonide/formoterol (ICS/L ABA) with tiotropi[INVESTIGATOR_496865]-severe COPD patients. These studies have reported greater improvements in 
lung function, HRQoL, hospi[INVESTIGATOR_496866], compared to dual 
(ICS/LABA) or LAMA alone, thus supporting the use of triple therapy  in COPD .These 
studies have also shown that the number and t ype of reported adverse events (AE) were 
generally similar with administration of dual or monotherap y doses for periods of up to 
one year, and were mostly  related to their pharmacological mode of action.
GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’triple therapy  of a 
ICS/LAMA/LABA combination [ fluticasone furoate (FF)/ umeclidinium 
(UMEC)/ vilanterol (VI) (100/62.5/25 mcg)] in a single inhaler, with the aim of providing 
a new treatment option for the management of s ymptomatic COPD patients at risk for 
exacerbations which will reduce the exacerbation frequency , allow for a reduced burden 
of polypharmacy , convenience, and increase the potential for improvement in lung 
function, HRQoL and s ymptom control over established dual/monotherapi[INVESTIGATOR_014]. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
11[COMPANY_004] conducted a Phase III study  comparing once -daily FF/UMEC/VI to twice -daily 
budesonide/formoterol (400/12 mcg) in COPD participants that were s ymptomatic and at 
risk of an exacerbation despi[INVESTIGATOR_496867] (CTT116853). 
FF/UMEC/VI demonstrated statistically  significant improvements in trough FEV 1, a 
statistically  significant reduction in the annual rate of moderate or severe COPD 
exacerbations, and a statistically  significant reduction of COPD sy mptoms (using 
Exacerbations and Chronic Pulmonary  Disease –Respi[INVESTIGATOR_244774] [ EXACT-RS]) 
when compared to budesonide/formoterol. Additionally , clinically meaningful 
improvements from baseline in St. George’s Respi[INVESTIGATOR_21606] ( SGRQ)total 
score were observed, with a statistically  significant improvement compared to 
budesonide/formoterol. This Phase III study  provided compelling efficacy  data compared 
with an establ ished ICS/LABA and demonstrated the clinical value of single inhaler 
triple-therapy compared to I CS/LABA therapy  in patients with COPD. 
As fixed dose combinations of LAMA/LABA therap y remain relativel y new, and ICS 
monotherap y is not indicated for the tre atment of COPD, the two most frequent treatment 
pathways that lead to ‘open’ triple therapy  are the escalation of therap y from either an 
ICS/LABA fixed dose combination or from LAMA monotherap y.A prior study  
demonstrated that participants with COPD may  remain symptomatic despi[INVESTIGATOR_496868] y.Participants that remain edsymptomatic despi[INVESTIGATOR_496869] , steppedup to ‘open’ triple therap y by [CONTACT_496952]/LABA therap y, which resulted in greater improvements inlung function and 
HRQoL, compared LAMA monotherapy .
The primary  purpose of this study  is to evaluate lung function and HRQoLafter 84 day s 
of treatment with a single inhaler triple therapy  combination of FF/ UMEC/VI 
(100/62.5/25 mcg) once daily  via the E LLIPTA™compared with tiotropi[INVESTIGATOR_1890] (18mcg) 
once daily, in a patient population appropriate for triple therapy .
Objectives and Endpoints:
Objectives Endpoints
Primary
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to tiotropi[INVESTIGATOR_496870] 12 weeks of 
treatment on lung functionPrimary
Change from baseline in trough FEV 1at 
Week 12 (Day 85)
Secondary 
Change from baseline in trough FEV 1
on Day 28and Day 84 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
12Objectives Endpoints
Other
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on Health StatusProportion of responders based on the St 
George’s Respi[INVESTIGATOR_21606] 
(SGRQ)Total Score at Week 4 and
Week 12
Change from baseline in SGRQ Total 
Score atWeek 4 and Week 12
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on Health StatusProportion of responders based on the 
COPD Assessment Test ( CAT)Total 
Score at Week 4 and Week 12
Change from baseline in CA T Total 
Score atWeek 4 and Week 12
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on COPD exacerbationsModerate or severe exacerbation event
Safety
To evaluate the safet y profileofsingle 
inhaler triple therap y (FF/UMEC/VI ) 
compared to tiotropi[INVESTIGATOR_496872] 12 weeks
of treatment Incidence of adverse events
Vital signs
Overall Design:
This is a Phase IV, 12-week, randomised, double -blind,double-dummy, parallel group ,
multicent restudy evaluating once-dailysingle inhaler triple therapy  (FF/UMEC/VI ) 
delivered via the ELLIPTA, compared to once daily  tiotropi[INVESTIGATOR_1890], in participants with 
COPD.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
13Study design schema
Eligible participants at Screening (Visit 1) will be current or former smoke rs, with an 
established clinical history of COPD, receiving daily  maintenance therap y with 
tiotropi[INVESTIGATOR_496873] 3 months (no I CS or LABA maintenance therapy is allowed 
during the 3 months prior to screening), with a post- bronchodilator FEV 1of <50% 
predicted (or <80 % predicted with a documented history  of at least 2 moderate or 1 
severe [hospi[INVESTIGATOR_057]] exacerbation in the last 12 months) and a CAT score of 10. 
Participants will be requested to participate in the study  for approximately  17 weeks, 
consisting of a 4 -week run-in period, 12-week treatment period and a 1- week follow -up 
period. 
Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre-screening Visit (Visit 0 ), 
including the in formed consent process, must be completed prior to an y 
protocol-required changes to a participant’s usual COPD treatment and the 
initiation of any Visit 1 procedures. Participants will continue treatment with 
their regular (i.e. pre -study) tiotropi[INVESTIGATOR_496874] -screening 
period.
Screening/run- in: Eligible participants will be allowed to continue their usual 
tiotropi[INVESTIGATOR_496875], Visit 
1.  On the morning of the Screening Visit participants will refrain from taking 
their morning dose of tiotropi[INVESTIGATOR_1890] . Participants who meet all of the eligibility 
criteria at Visit 1 (Screening), will enter the 4 -week run-in period.
Participants will discontinue existing tiotropi[INVESTIGATOR_496876]-
labeltiotropi[INVESTIGATOR_1890] 18 mcgvia the HandiHaler once daily  plus placebo via the 
ELLIPTA. Participants will not use any  other COPD medications (except for 
those allowed per protocol).  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
14During the run-in period participants will also take placebo via the ELLIPTA in 
addition to open -label tiotropi[INVESTIGATOR_1890]. This will familiarise participants with the use 
of the ELLIPTA device and will help ensure participants are compliant and use 
both devices as instructed.
Participants will be provided with short -acting albuterol/salbutamol to be used 
on an as-needed basis (rescue medication) throughout the study . At Screening, 
each participant will be instructed on the proper use of the ELLIPTA and 
HandiHaler and will self -administer their first doses of their run -in treatment 
during the Scr eening Visit. On the morning of the other study  visits (Visit 2 
onwards), participants will refrain from taking their morning dose of stud y 
treatment until instructed to do so by  [CONTACT_6477]. 
Randomi sation/treatment: On the morning of the day  before the 
Randomisation Visit(Visit 2), participants will take their last dose of run-in 
treatment and will not use an y other COPD medications (except for those 
allowed per protocol.  Rescue albuterol/salbutamol can be used throughout the 
study as-needed but mu st be withheld for at least 4 hours prior to conducting 
spi[INVESTIGATOR_038] .
At Visit 2 (the Randomisation Visit), participants who meet all of the 
randomisation criteriawill be randomised 1:1 to receive one the following 
double-blind study  treatments for 84 day s:
FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once dail y in the morning
+ placebo to match tiotropi[INVESTIGATOR_496877]
Tiotropi[INVESTIGATOR_1890] 18 mcg via HandiHaler once dail y in the morning
+ placebo via the ELLIPTA once dail y in the morning
Participants may  continue their study -supplied rescue albuterol/salbutamol. On 
the morning of Visits [ADDRESS_638769] dose of stud y treatment in the clinic on Day 84 
and then return to the clinic on Day  85 (Visit 5) for their final clinical 
assessments. Participants are expected on non -clinic visit day s to take their study  
treatment at home in the morning at approximately  the same time each day, as 
directed b y the clinic. 
Safety/follow -up: A safety follow-up telephone contact [CONTACT_496953] 
(Visit 6) will be condu cted approximately  7 days after the participant completes 
all of the protocol -defined procedures for V isit 5/End of Study  (EOS)or, if 
applicable, the Study Treatment Discontinuation Visit. A participant will be 
considered to have completed the study  when they have completed all phases of 
the study including screening, run -in, the randomised treatment phase, and
safety follow-up. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638770] permanentl y discontinue study 
treatment, every  effort should be made by  [CONTACT_737]/staff to keep the participant in 
the study and complete all remaining protocol specified clinic visits .However,a 
participant may  voluntarily  withdraw from participation in this study  at any time. The 
Investigator may  also, at his or her discretion, withdraw a participant from further study  
participation. Participants who are withdrawn from the study  will not be replaced.
A participant will be considered to h ave completed the study  when they  have completed 
allphases of the stud y including screening, run -in, the randomised treatment phase, and
safety follow-up.
Number of Participant s:
Approximately  848participants with advanced COPD will enter the run- inperiod,in 
order to randomi se approximately  780participants, in order to achieve an estimated 702 
evaluble participants .
Approximately  100 centres globall y will be required to recruit the study.
Treatment Groups and Duration:
Participants who meet all the eligibility criteria and who have successfull y completed all 
protocol procedures at Screening will enter the 4-weekrun-in period andwill take open-
label tiotropi[INVESTIGATOR_1890] 18 mcg via the HandiHaler once daily  plus placebo via the 
ELLIPTA .Following the run- in period, eligible participants will be randomised (1:1) to 
one of the following double -blind, double-dummytreatment groups for 84 day s:
Either:
FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once dail y in the morning
      +  placebo to match tiotropi[INVESTIGATOR_496878],
Tiotropi[INVESTIGATOR_1890] 18 mcg via HandiHaler once dail y in the morning
       + placebo via the ELLIPTA once daily  in the morning
The ELLIPTA contains 30 doses (FF/UMEC/VI or placebo) and participants will be
instructed to admini ster one dose from their ELLIPTA once dail y in the morning.
Tiotropi[INVESTIGATOR_496879] : Contents of 1 capsule (18 mcg) inhaled once dail y 
using HandiHaler device. Note: To ensure drug delivery, two inhalations of the contents 
of each capsule should be performed. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
16Key Elements of Analysis Plan :
The primary  objective of this study  is to compare single inhaler triple therapy  
(FF/UMEC/VI) withtiotropi[INVESTIGATOR_1890] (TIO) in participants with COPD who have received 
tiotropi[INVESTIGATOR_496880] s ymptoms as measured b y CAT 10.The primary  
endpoint is trough FEV ₁at Week 12 (Day  85). The primary  analysis is the comparison of 
this endpoint between FF/UMEC/VI  and tiotropi[INVESTIGATOR_1890].   
The null hy pothesis is that there is no difference between treatment groups.
H0: T1 – T2 = 0
The alternative hy pothesis is there is a diffe rence between treatment groups.
H1: T1 – T2 0
where T 1and T2are the treatment means for FF/UMEC/VI and TIO, respectively .
The primary analyses will be based on the ITT popula tion using only  data collected on
treatment, the analysis will evaluate the endpoint of trough FEV 1using a mixed model 
repeated measures (MMRM) anal ysis, including on-treatment trough FEV 1recorded at 
each of visits, Day  28, Day 84 and Day  85. The model will include covariates of baseline 
FEV1, visit, geographical region , treatment and visit by  [CONTACT_420780]. A visit by  
[CONTACT_496954] y. The variance -covariance matrix will be assumed unstructured.
Estimated differences between FF/UMEC/VI and tiotropi[INVESTIGATOR_496881] 95% confidence intervals (CIs) for the difference and p -values.
The details of the statistical anal ysis methods for the secondary  efficacy endpoint will be 
provided in the Reporting and Anal ysis Plan (RAP).  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
172. SCHEDULE OF ACTIVITI ES (SOA )
Protocol ActivityPre-
ScreenScreen Treatment Follow -up
Visit 0Visit 1 
Screen/ 
Run-inVisit [ADDRESS_638771]
Study Day-56 to  
-28Day - 28 Day 1 Day 28 Day 84 Day 85 Day 91
Week -8 to -4 -4 0 4 12 12 13
Window-3/+8d
(Day - 31 
to -21)-4/+2d 
(Day 24 
to 30)-4/+2d
(Day 80 
to 86)-1/+4d
(Day 90 
to 95)
Written Informed 
Consenta,X X
Genetic In formed 
ConsentbX X
Demographyc X X
Medical History, including 
cardiovascular historyX
COPD and Exacerbation 
HistoryX
Concomitant Medication 
AssessmentX X X X X X X
Inclusion/Exclusion 
CriteriaX X
Smoking History X
Smoking status X X X
Smoking Cessation 
CounsellingX X X
Register Visit in IWRS X X X X X X X
CATd X X X X
SGRQ -Cd X X X
Reversibility Testinge X
Trough Spi[INVESTIGATOR_94214] X X X X
Device training and 
registrationX X
Exacerbation 
AssessmentX X X X X X
Physical examinationg X X X
Adverse Events 
AssessmentX X X X X X
Vital signsh X X X
ECG X
Chest X -rayi X
Oropharyngeal 
examinationX X X X X
Blood Draw for Genetics 
resea rchjX
Hematology/biochemistryk X
Urine Pregnancy Test l X X X
Hepatitis B and C tests X 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
18Protocol ActivityPre-
ScreenScreen Treatment Follow -up
Visit 0Visit 1 
Screen/ 
Run-inVisit [ADDRESS_638772]
Study Day-56 to  
-28Day - 28 Day 1 Day 28 Day 84 Day 85 Day 91
Week -8 to -4 -4 0 4 12 12 13
Window-3/+8d
(Day - 31 
to -21)-4/+2d 
(Day 24 
to 30)-4/+2d
(Day 80 
to 86)-1/+4d
(Day 90 
to 95)
Dispense run -in treatment X
Dispense study treatment X X
Administer run -in 
treatment in clinic mX
Administer st udy 
treatment in clinic nX X X
Assess run -in treatment 
complianceX
Collect run -in treatment X
Assess study treatment 
complianceX X X
Collect study treatment X X X
Dispense 
albuterol/salbutamolX X X X
Collect 
albut erol/salbutamolX X XXX
Dispense paper Medical 
Problems worksheet XX X X X
Review paper Medical 
Problems worksheetX X X XXX 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638773] be 
obtained prior to obtaining a genetic blood sample. The sample can be collected at any time after Visit 2, 
providing consent is obtained.
c. Demography may be captured at either the Pre -screen Visit or Screening Visit.
d. SGRQ -C and CAT will be completed electronically, and should be conducted in the following order and before 
other study assessments: CAT, SGRQ -C.
e. At Screening Visit [ADDRESS_638774] -bronchodilator spi[INVESTIGATOR_496882]. Participants are required to 
withhold their usual morning doses of their COPD meds including rescue albuterol/salbutamol for the protocol  
designated period prior to reversibility testing.
f. Pre-bronchodilator spir ometry will be performed pre -dose at 30 mins and 5 mins prior to taking the morning                                                                       
dose of study treatme nt, between 6am and 11am and after withholding rescue albuterol/sal butamol for ≥[ADDRESS_638775] X -ray is required at Screening (or historical x- ray obtained within 3 months p rior to Screening) and at                                                                                                    
anytime there is a suspected pneumonia or a mod/severe exacerbation
j. Genetic consent must be ob tained prior to obtaining a blood sample.
k. Hematology and chemistry panels will include full and differential blood count and liver chemistry. See 
Appendix 8. 
l. All female Participants of child bearing potential will hav e a urine pregnancy test at Visits 1, 4 and Study 
Treatment Discontinuation Visit (if applicable).
m. Participants must withhold their morning dose of existing COPD medication/study treatment and not take their 
treatment until instructed to do so by [CONTACT_496955]
n. Participants must withhold their morning dose of study treatment at each clinic visit and not take their study               
treatment until instructed to do so by [CONTACT_496956], 
SGRQ-C, vitals, ECG, spi[INVESTIGATOR_038] , clinical lab assessments.
3. INTRODUCTION
3.1. Study Rationale
Chronic obstructive pulmonary  disease (COPD) guidelines advocate the use of long-
acting muscarinic receptor antagonists (LAMA) added to the combination of an inhaled 
corticosteroid (ICS) plus a long-acting β 2-adrenergic receptor agonists (LABA) as second 
line therap y for the most advanced patients with sign ificant symptoms and a high risk of 
exacerbations. Regular treatment with I CS-containing regimens has been reported to 
improve respi[INVESTIGATOR_23908], lung function, health related quality  of life (HRQoL) and 
reduce the frequency COPD exacerbation sin patients with a forced expi[INVESTIGATOR_496883] 1 
second (FEV1) <60% predicted [Aaron, 2007;Cazzola, 2007; Hanania, 2012; Jung, 
2012;Siler, 2015;Welte, 2009].
Population based studies of COPD treatment patterns demonstrate that ‘open’triple 
therapy (use of ICS/LAMA/L ABA delivered via multiple inhalers) is already  widely used 
in the real -life management of COPD. In 2011, 26 % of patients in the [LOCATION_002] ( US)
who were taking controller medicines for the treatment of COPD were taking an ‘open’
triple therap y, typi[INVESTIGATOR_496864]/salmeterol (ICS/LABA) to  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
20tiotropi[INVESTIGATOR_1890] (L AMA) or vice versa [ Wolters, 2012]. A study  in the [LOCATION_008] ( [LOCATION_006])
Clinical Practice Research Database (CPRD) revealed that over a two year period of time, 
35% of COPD patients initially prescribed a LAMA and 39 % initially  prescribed an 
ICS/LABA stepped up to an ‘open’triple therapy  regimen [ Wurst, 2013]. In the four year 
long-term safet y study conducted with tiotropi[INVESTIGATOR_1890], 46 % of patients were receiving a 
concurrent fixed combination of I CS/LABA in addition to tiotropi[INVESTIGATOR_1890] [ Tashkin, 2008]. 
A number of studies have assessed the use of an ‘open’triple therapy  of fluticasone 
propi[INVESTIGATOR_16847]/salmeterol or budesonide/formoterol (ICS/L ABA) with tiotropi[INVESTIGATOR_496865]-severe COPD patients. These studies have reported greater improvement s in 
lung function, HRQoL, hospi[INVESTIGATOR_496866], compared to dual 
(ICS/LABA) or LAMA alone, thus supporting the use of triple therapy  in COPD [ Aaron, 
2007;Cazzola, 2007; Hanania, 2012; Jung, 2012;Siler, 2015;Welte, 2009]. These 
studies have also shown that the number and t ype of reported adverse events (AE) were 
generally similar with administra tion of dual or monotherap y doses for periods of up to 
one year, and were mostly  related to their pharmacological mode of action.
GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’triple therapy  of a 
ICS/LAMA/LABA combination [ fluticasone furoate (FF)/ umeclidinium 
(UMEC)/ vilanterol (VI) (100/62.5/25 mcg)] in a single inhaler, with the aim of providing 
a new treatment option for the management of s ymptomatic COPD patients at risk for 
exacerbations which will reduce the exacerbation frequenc y, allow for a reduced burden 
of polypharmacy , convenience, and increase the potential for improvement in lung 
function, HRQoL and s ymptom control over established dual/monotherapi[INVESTIGATOR_014].
[COMPANY_004] conducted a Phase III study  comparing once -daily FF/UMEC/VI to twic e-daily 
budesonide/formoterol (400/12 mcg) in COPD participants that were s ymptomatic and at 
risk of an exacerbation despi[INVESTIGATOR_496867] (CTT116853). 
FF/UMEC/VI demonstrated statistically  significant improvements in trough FEV 1, a 
statistically significant reduction in the annual rate of moderate or severe COPD 
exacerbations, and a statistically  significant reduction of COPD sy mptoms (using 
Exacerbations and Chronic Pulmonary  Disease –Respi[INVESTIGATOR_244774] [ EXACT-RS]) 
when compared to bude sonide/formoterol. Additionally , clinically meaningful 
improvements from baseline in St. George’s Respi[INVESTIGATOR_21606] ( SGRQ)total 
score were observed, with a statistically  significant improvement compared to
budesonide/formoterol [Lipson, 2017].This Phase III stud y provided compelling efficacy  
data compared with an established I CS/LABA and demonstrated the clinical value of 
single inhaler triple-therapy compared to ICS/LABA therapy  in patients with COPD. 
As fixed dose combinations of LAMA/LABA therap y remain relativel y new, and ICS 
monotherap y is not indicated for the treatment of COPD, the two most frequent treatment 
pathways that lead to ‘open’ triple therapy  are the escalation of therap y from either an 
ICS/LABA fixed dose c ombination or from LAMA monotherap y. A prior study  
demonstrated that patient swith COPD may  remain sy mptomatic despi[INVESTIGATOR_496868] y [Dransfield, 2011 ]. Patients that remained sy mptomatic 
despi[INVESTIGATOR_496884] y, stepped up to ‘open’ triple therap y by [CONTACT_113869] I CS/LABA therapy , which resulted in greater improvements in lung function  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
21and HRQoL, compared LAMA monotherap y [Aaron, 2007; Cazzola , 2007; Hanania , 
2012; Jung, 2012; Siler , 2015; Welte, 2009].
The primary  purpose of this study  is to evaluate lung function and HRQoLafter 84 day s 
of treatment with a single inhaler triple therapy  combination of FF/ UMEC/VI 
(100/62.5/25 mcg) once daily  via the ELLIPTA compared withtiotropi[INVESTIGATOR_1890] (18mcg) once 
daily, in a patient population appropriate for triple therapy .
3.2. Background
Chronic obstructive pulmonary  disease is a progressive disease characterised by  
[CONTACT_496957][INVESTIGATOR_496885], increased sputum production, dy spnoea and 
wheezing.  
In 2011, the Global Initiative for Chronic Obstructive Lung Disease [GOLD, 2011]
issued a guideline that outlined a new classification sy stem for COPD , using the ABCD 
assessment tool, which aimed to more comprehensively  assess disease severity  and guide 
therapychoice, ultimately  improving COPD management .A [ADDRESS_638776] had a 
hospi[INVESTIGATOR_496886], regardless of GOLD status [ GOLD, 2013 ].
GOLD released a revised guideline in 2017 that separates spi[INVESTIGATOR_496887] y (Table 1) 
[GOLD, 2017].  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
22Table 1GOLD 2017 Classification
GOLDABCD
ClassificationRisk Class Determinant Symptom Category 
Determinant*
A:  Low risk, 
less symptoms≤1 exacerbation, prior year mMRC <2;  CAT <10
B:  Low risk, 
more symptoms≤1 exacerbation, prior year mMRC 2;  CAT ≥10
C:  High risk, 
less symptoms≥2 exacerbations, prior year OR1 
leading to hospi[INVESTIGATOR_11956] , prior 
yearmMRC <2;  CAT <10
D:  High risk , 
more symptoms≥2 exacerbations, prior year OR1 
leading to hospi[INVESTIGATOR_11956] , prior 
yearmMRC 2;  CAT ≥10
* -Symptomatic category determined by [CONTACT_496958] (mMRC) or COPD Assessment Test 
(CAT) score.
GOLD Airflow 
Limitatio nSeverity FEV1(% predicted)
GOLD 1 Mild 80
GOLD 2 Moderate 50 – 79 
GOLD 3 Severe 30 – 49 
GOLD 4 Very Severe <30
The GOLD2017guideline also outlined suggested management strategies for COPD 
based upon disease severity , including escalation as well as de -escalation strategies . For 
milder patients (GOLD Group A), the guidelines encourage active risk reduction (e.g., 
smoking cessation and influenza vaccination) with the addition of bronchodilators.  
However, as disease severity  increases, the guid elines recommend an incremental 
approach to pharmacological treatment, involving the use of combinations of drug classes 
with different or complementary  mechanisms of action [ Celli, 2004; GOLD, 2017].  
Long-actingbronchodilators (LAMAsor LABAs) have been shown to relieve sy mptoms, 
increase exercise capacity, improve health -related quality  of life and reduce COPD 
exacerbations to a greater extent than short acting 2adrenergic receptor agonists .  For 
advanced cas es, or those with repeated exacerbations, the incorporation of ICS or triple 
therapy, is recommended. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
233.3. Benefit/Risk A ssessment
Summaries of findings from both clinical and non-clinical studies conducted with 
[COMPANY_004]2834425 (FF/UMEC/VI ) can be found in the I nvestigator’s Brochure (IB).  The 
safety information for tiotropi[INVESTIGATOR_496888].  The 
current safet y profile for FF/UMEC/VI (100/62.5/25 mcg), based on data available to 
date, is consistent with the pharmacological classes of the components.  The following 
section outlines the risk of assessment and mitigation strategy  for this protocol. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
243.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [COMPANY_004]2834425 (FF/UMEC/VI), [COMPANY_004]573719 (UMEC), GW642444 (vilanterol), GW685698 (fluticasone furoate)
Pneumonia in participant s with COPD Pneumonia is a class concern for an y ICS-
containing product for the treatment of 
COPD.  
In a study  (CTT116853) in 1 810 
randomised COPD participants treated with 
FF/UMEC/VI or budesonide/formoterol 
(BUD/FOR) for up to 24 weeks ( Intent-To-
Treat [ITT]Population), or up to 52 weeks 
(subset of 430 participants; EXT 
Population), the incidence of events in the 
pneumonia AEs of special interest (AESI) 
group was 2.2 % and 0.8 % for 
FF/UMEC/VI and BUD/FOR, respectivel y 
in the ITT Population, and 1.9 % and 1.8 % 
for FF/UMEC/VI and BUD/FOR, 
respectivel y, in the EXT Population.  There 
was one fatal case of pneumonia in a 
participan t who received FF/UMEC/VI.
The incidence of pneumonia with 
FF/UMEC/VI in this study  was in line with 
the incidence of pneumonia seen in 24 week 
studies with F/VI (<1 -2% with FF/VI 
100/25) and less than that observed in 52 
week exacerbations studies with F F/VI (6% -Participants will be informed of the risk in 
the informed consent.
-Investigators are informed of the risk in 
the IB
-Investigators will be instructed to remain 
vigilant for the possible development of 
pneumonia in participants with COPD as the 
clinical features of such infections overlap 
with the sy mptoms of COPD exacerbations. 
For suspected cases of pneumonia, 
investigators will be encouraged to arrange 
a chest x-ray within 48 hours of diagnosis 
(Section 12.5.2) and to treat appropriatel y.
-Appropriate e xclusion criteria as specified 
in Section 6.2of the protocol i.e
-Instream review of blinded AE/SAE 
reports. 
-All diagnoses of pneumonia 
(radiographicall y confirmed or 
unconfirmed) must be reported as an AE or 
SAE (if applicable) as specified in Section 
9.2.7.
-Chest X-ray read required at baseline and 
whenever a participant has suspected 
pneumonia or mod/severe exacer bations 
during the stud y.  
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
25Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
with FF/VI 100/25) [ Dransfield , 2013].  
Similarly, the incidence of pneumonia with 
FF/UMEC/VI was less than that observed in 
a 12 month exacerbation trial with 
BUD/FOR (6.4 %) [Sharafkhaneh, 2012].
Prior studies with FF/VI have demonstrated 
risk factors associated with a higher risk of 
pneumonia in participants with COPD (e.g., 
advanced age, poor lung function, low body 
mass index ( BMI), current smoking, and a 
prior history of pneumonia) [ Crim, 2009].
These risk factors were present in some 
participants with pneumonia in study  
CTT116853 with FF/UMEC/VI ; however, 
the low number of pneumonia events 
reported in this study  precludes drawing any  
definite conclusions about risk factors.  
Theseriskfactors should be taken into 
consideration when using an I CS in 
participant s with COPD. Pneumonia risk 
will be important in the benefit -risk 
assessment for FF/UMEC/VI  in COPD 
participant s, hence a robust risk mitigation 
strategy is being proposed.
Pharmacovigilance Risk Assessment 
Committee (PRAC)recently conducted an 
Article 31 review to evaluate the risk of 
pneumonia with use of ICS in participants  
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
26Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
with COPD.  The PRAC review confirmed 
that COPD participants treated with ICS are 
at increased risk of pneumonia; however, 
the Committee’s view was that the benefits 
of ICS continue to outweigh their risks.  The 
PRAC also looked whether there were an y 
differences in the risk of pneumonia 
between these produces, and did not find 
conclusive e vidence of such difference.
Decreased bone mineral density and 
associated fractures Reduction in bone density, and the 
subsequent risk of fractures, is a known 
potential risk with corticosteroids.  There 
may be a modest increase in risk of fracture 
among participants with COPD treated with 
ICS, but the results are not consistent across 
individual studies [ Christensson, 2008; 
Lehouck, 2011; Weldon , 2009].
In study CTT116853, the incidence of 
events in the decreased bone mineral densit y 
and associated fracture AESI  group was 
low, with an incidence of 0.4 % and 0.7 % 
in the FF/UMEC/VI and BUD/FOR 
treatment groups, respectively  in the ITT 
Population up to 24 weeks and 0.5 % in 
both treatment groups in the EXT 
Population up to 52 weeks.  The majority  of -Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB.
-Instream review of blinded AE/SAE 
reports. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
27Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
the fractures in both treatment groups were 
traumatic in nature.
Adrenalsuppression Oral corticosteroids are known to have an 
effect on the h ypothalamic -pi[INVESTIGATOR_2117]-adrenal 
(HPA) axis leading to reduction in cortisol 
production.  Due to the low dose and low 
systemic exposure with ICS, this potential 
effect is not clear, nor is the possible impact 
of any change in cortisol.
The effect of FF/UMEC/VI on cortisol 
levels has not been studie d.  In study 
CTT116853, no events were reported in the 
adrenal suppression AESI group for 
FF/UMEC/VI and BUD/FOR.
With respect to the FF/VI clinical 
development program me, a formal HPA 
study, using 24 -hour serum cortisol 
measurements, was performed.  In addition, 
multiple studies with COPD (and asthma) 
participants monitored urinary  cortisol.  
These studies did not show a clinicall y 
relevant effect of FF/VI 100/[ADDRESS_638777] 
received significant amounts for l ong 
periods of time, will be more susceptible to - Investigators are informed of the risk in 
the IB.
-Instream review of blinded AE/SAE 
reports. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
28Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
this risk of adrenal suppression.  
The proposed dose (100 mcg) of inhaled FF 
in this study  is unlikely  to lead to clinically  
significant changes in the treatment period 
since systemic exposure is low. 
Corticosteroid Associated Eye Disorders Systemic ocular effects ( e.g.cataract and 
glaucoma) may  occur with any  inhaled 
corticosteroid, particularly  at high do ses 
prescribed for long periods. However, these 
effects are much less likely  to occur with 
inhaled corticosteroids compared with oral 
corticosteroids.
In study CTT116853, the incidence of 
events in the ocular effects AESI  group was 
low, with an incidence o f 0.1% and 0.4 % 
in the FF/UMEC/VI and BUD/FOR 
treatment groups, respectively , in the ITT 
Population up to 24 weeks.  There were no 
events reported in the ocular effects AESI in 
the EXT Population up to 52 weeks.
During studies with FF and FF/VI in asthma
participants, and with FF/VI  and UMEC/VI 
in COPD participants, no associated effect 
on ocular disorders was observed. In 
addition, no effects on lens opacification 
were observed on formal ophthalmic -Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB.
-Appropriate exclusion criteria as specified 
in Section 6.2of the protocol.
-Instream review of blinded AE/SAE 
reports
-If a risk is suspected, participants should 
receive appropriate treatment 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
29Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
assessments in a study  with FF/VI, FF and 
FP in participants with asthma.
Serious cardiovascular events Cardiovascular (CV) effects are a potential 
class effect associated with anti- muscarinic 
and beta-agonist thera pi[INVESTIGATOR_014].
In the COPD population, there is a high 
prevalence of concurrent CV disease and the 
prevalence of CV co -morbidities increases 
with worsening severit y of COPD.
In study CTT116853 [Lipson, 2017], 
approximately  two-thirds of all participants 
reported CV risk factors at baseline.  In this 
study, CV effects were the most frequentl y 
reported AESI, with a similar incidence 
between FF/UMEC/VI and BUD/FOR 
treatment groups in the ITT Population up 
to 24 weeks (4.5 % and 5.2 %, respectively ) 
and the EXT Population up to 52 weeks 
(8.6% and 10 %, respectively ).  Within 
subgroups of CV effects, hy pertension was 
reported most frequentl y and with a 
numericall y higher incidence with 
BUD/FOR (2.3 %) compared with 
FF/UMEC/VI (1.3 %) in the ITT Population 
up to 24 weeks, but with a similar incidence 
in the EXT Population up to 52 weeks 
(0.9% to 1.0 % across treatment groups).  -Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB.
-Appropriate e xclusion criteria as specified 
in Section 6.2of the protocol , including 
ECG inclusion criteria
-Vital sign assessments (heart rate and 
blood pressure) as per protocol
-Protocol defined stoppi[INVESTIGATOR_417419] 8.1.1
-Instream review of blinded AE/SAE 
reports. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
30Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Cardiac arrh ythmias were reported the next 
most frequently  and occurred with an 
incidence of 1.2 % in both treatment groups 
in the ITT Population up to 24 weeks and 
with an incidence of 1.9 % and 3.6 % in the 
FF/UMEC/VI and BUD/FOR groups in the 
EXT Population up to 52 weeks.
The incidence of serious events in the CV 
effects AESI was low, with an incidence of 
1.0% and 1.1 % in the FF/UMEC/VI and 
BUD/FOR groups, respectively, in the ITT 
Population to 24 weeks, and 2.9 % and 
1.4% in the FF/UMEC/VI and BUD/FOR 
groups, respectively , in the EXT Population 
up to 52 weeks.  The absolute numbers of 
fatal events in CV effects AESI  was low in 
the study, despi[INVESTIGATOR_496889] a number of CV co -
morbidities at baseline.
A pre-specified Major Adverse Cardiac 
Event (MACE) analy sis was conducted in 
CTT116853, with broad MACE defined as: 
ischemic heart disease Standardised 
MedDRA Queries (SMQ)excluding 
fatalities, plus central nervous sy stem 
haemorrhages and cerebrovascular 
conditions SMQ excluding fatalities, plus 
adjudicated cardiovascular deaths.  The 
narrow MACE definition included only  the  
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
31Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
preferred terms of m yocardial ischaemia 
and acute m yocardial infarction in place of 
the ischaemic heart disease SMQ.  Overall, 
the absolute number of MACE events using 
either the broad or narrow definition was 
low both in the ITT Population up to 24 
weeks and the EXT Population up to 52 
weeks.  No clinically  relevant differences 
were observed between FF/UMEC/VI and 
BUD/FOR based on narrow and broad 
MACE anal ysis both in the ITT Population 
up to [ADDRESS_638778] of FF/UMEC/VI on the QT 
interval has not been evaluated in a 
thorough QT (TQT) study. TQT studies for 
FF/VI and UMEC/VI did not show 
clinically relevant effects on QT interva l at 
clinical doses of FF, UMEC and VI. 
The CV safet y profile of FF/UMEC/VI was 
generally consistent with that of FF/VI and 
UMEC/VI .
Hypersensitivity Hypersensitivity  reactions are unlikel y to -Participants will be informed about the 
risk in the informed consent.  Participants  
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
32Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
affect the majorit y of participants .
In study CTT116853, in the ITT Population 
up to 24 weeks, events in the 
hypersensitivity  AESI group occurred at 
low incidences in the FF/UMEC/VI  and 
BUD/FOR treatment groups (1.1 % in both 
groups).  Similarly , in the EXT Population 
up to 52 weeks, events in the 
hypersensitivity  AESI group occurred at 
low incidences (1.4 % and 0.5 % in the 
FF/UMEC/VI and BUD/FOR groups, 
respectivel y).  On-treatment hy persensitivity  
serious AESI events occurred at low 
frequency .
Risk factors for h ypersensitivity  are poorl y 
understood, but may  include exposure to 
infectious diseases during early childhood, 
environmental pollution, allergen level, and 
dietary changes [ Niggemann, 2014; De 
Bisschop, 2012].  Although h ypersensitivity  
reactions are unlikel y to affect the majorit y 
of participant s, there may be a few 
individuals who experience allergic 
reactions; they  will need to be managed on a 
case by [CONTACT_413].will be advised to seek medical treatment if 
any signs of h ypersensitivity  occur.
-Investigators are informed of the risk in 
the IB.
-Appropriate exclusion criteria as specified 
in Section 6.2of the protocol.
-Instream review of blinded AE/SAE 
reports.
Narrow angle gla ucoma Rare reports of angle closure glaucoma 
(which may  lead into blindness) have been 
associated with nebulised ipratropi[INVESTIGATOR_1890] -Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
33Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
bromide and salbutamol [ Packe, 1984].
The incidence of narrow angle glaucoma in 
the COPD population associate d with the 
use if inhaled bronchodilators (including 
LAMAs and LABAs) is relatively  low.
In CTT116853, in the ITT Population up to 
24 weeks, events in the glaucoma SMQ 
were reported as an incidence of 0.1% to 
0.4% in the FF/UMEC/VI and BUD/FOR 
arms, respe ctively.  In the EXT Population 
up to 52 weeks, no events were reported in 
either treatment arm.
In the UMEC/VI development programme , 
there was one report (<1 %) of angle closure 
glaucoma (UMEC/VI 62.5/25 mcg).-Appropriate exclusion criteria as specified 
in Section 6.2of the protocol.
-Instream review of blinded AE/SAE 
reports.
Bladder outlet obstruct ion, dysuria, and 
urinary retentionBladder outlet obstruction and urinary  
retention are class effects seen with 
antimuscarinics.
In study CTT116853, in the ITT Population 
up to 24 weeks, the incidence of events in 
the urinary  retention AESI  group was low 
(0.1% and 0.0 % for FF/UMEC/VI  and 
BUD/FOR, respectivel y) in both treatment 
groups.  There were no events of urinary  
retention reported in either group in the 
EXT Population up to 52 weeks.  There 
were no serious events in the urinary  -Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB.
-Appropriate exclusion crite ria as specified 
in Section 6.2of the protocol.
-Instream review of blinded AE/SAE 
reports. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
34Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
retention AESI group in either treatment 
group in the ITT Population up to 24 weeks 
and the EXT Population up to 52 weeks.
Paradoxical bronchospasm The phenomenon of paradoxical 
bronchospasm may  occur in association 
with all inhaled medication and may  vary 
from mild to life threatening.
In study CTT 116853, the risk of 
paradoxical bronchospasm was evaluated 
through the AESI of asthma/bronchospasm.  
In the ITT Population up to 24 weeks, one 
participant reported an event in the 
athma/bronchospasm AESI  (PT ofwheezing 
in a participant on BUD/FOR; non -serious).  
There were no events reported in the EXT 
Population up to 52 weeks.-Participants will be informed about the 
risk in the informed consent.
-Investigators are informed of the risk in 
the IB.
-Instreamreview of blinded AE/SAE 
reports. 
 
 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
353.3.2. Risk Assessment for Tiotropi[INVESTIGATOR_195352] 18mcg
Tiotropi[INVESTIGATOR_96812] a marketed drug that contains tiotropi[INVESTIGATOR_1893] (18 mcg). A similar 
profile of undesirable effects as reported for anticholinergics (umeclidinium) may  occur
with tiotropi[INVESTIGATOR_1893]. The most common drug related adverse reactions are 
pharmacologically  predictable side effects for anti -cholinergic therap y, such as dry 
mouth, blurred vision, dizziness, headache and cough. Please refer to the authorised 
product label for further information on the risks of using Spi[INVESTIGATOR_342405]. In this 
study, tiotropi[INVESTIGATOR_496890]. 
Tiotropi[INVESTIGATOR_496891], therefore the risk mitigation strategy  for UMEC
component of [COMPANY_004]2834425 will be applicable for tiotropi[INVESTIGATOR_1890] . 
3.3.3. Benefit A ssessment
GlaxoSmithKline is developi[INVESTIGATOR_496892]/UMEC/VI in a single inhaler, with the aim of 
providing a new treatment option for the management of sy mptomatic COP Dparticipants 
at risk for exacerbations which will reduce the exacerbation frequency , allow for a 
reduced burden of poly pharmacy , convenience, and increase the potential for 
improvement in lung function, HRQoL , and symptom control over established 
dual/monotherapi[INVESTIGATOR_014].
Current risks have been identified for the FF/UMEC/VI  (100/62.5/25 mcg) combination 
based on the known pharmacology  of the individual components, FF, UMEC, and VI , 
alone or in combination .  These include key  risks of pneumonia and bone 
disorders/fractures from ICS -containing combinations, and the risk of adverse 
cardiovascular effects from L AMAand/or LABA-containing combinations.
In the US, the FF/VI combination is approved for the maintenance treatment of airflow 
obstruction and for reduction of exacerbations in COPD. The UMEC/VI combination is 
approved for maintenance treatment of airflow obstruction in COPD. UMEC is indicated 
for the long -term, once -daily, maintenance treatment of airflow obstruction in 
participant s with COPD.
In the EU, the FF/VI combination is app roved for the sy mptomatic treatment of adults 
with COPD with an FEV 1<70% predicted normal (post- bronchodilaotr) with an 
exacerbation history  despi[INVESTIGATOR_496893].  The UMEC/VI combination 
is approved as a maintenance bronchodilator to r elieve symptoms in adult participants 
with COPD. UMEC is approved as a maintenance bronchodilator treatment to relieve 
symptoms in adult participant s with COPD.
An appropriate safety  monitoring strategy  is being proposed for all risks associated with 
the FF/UMEC/VI combination, including the key  risks (Section 3.3.1).
Given the clinical experience with FF, UMEC, and VI, and that the associated risks with 
these compounds are anticipated from their known pharmacology , the potentia l benefit of 
a new therap y option in participants with moderate to severe COPD supports the further 
development of the closed triple combination. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
36Tiotropi[INVESTIGATOR_1890] (18 mcg) is a marketed drug for the COPD indication, and has an established 
benefit:risk profile.  Tiotropi[INVESTIGATOR_496894].
3.3.4. Overall Benefit:Risk Conclusion
Taking into account the measures taken to minimize risk to participants participating in 
this study , the potential risks identified in a ssociation with FF/UMEC/VI and tiotropi[INVESTIGATOR_496895] b y the anticipated benefits from active treatments that may be afforded to 
participants with COPD. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
374. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
To evaluate the effect of single inhaler 
triple therapy (FF/UMEC/VI) compared 
to Tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on lung functionPrimary
Change from baseline in trough FEV 1at 
Week 12 (Day 85)
Secondary 
Change from baseline in trough FEV 1at 
Week 4(Day 28)and Week 12 (Day 84)
Other
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to Tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on Health StatusProportion of responders based on the St 
George’s Respi[INVESTIGATOR_21606] 
(SGRQ)Total Score at Week 4 and 
Week 12
Change from baseline in SGRQ Total 
Score at Week 4 and Week 12
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to Tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on Health StatusProportion of responders based on the 
COPD Assessment Test ( CAT)Total 
Score atWeek 4 and Week 12
Change from baseline in CAT Total 
Score at Week 4 and Week 12
To evaluate the effect of single inhaler 
triple therap y (FF/UMEC/VI) compared 
to Tiotropi[INVESTIGATOR_496871] 12 weeks of 
treatment on COPD exacerbationsModerate or severe exacerbation event
Safety
To evaluate the safet y profile of single 
inhaler triple therap y (FF/UMEC/VI ) 
compared to Tiotropi[INVESTIGATOR_496872] 12 weeks
of treatment Incidence of adverse events
Vital signs 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
385. STUDY DESIGN
5.1. Overall Design
This is a Phase IV, 12-week, randomised, double -blind,double-dummy, parallel group ,
multicent restudy evaluating once-dailysingle inhaler triple therapy  (FF/UMEC/VI ) 
delivered via the ELLIPTA , compared to once daily  tiotropi[INVESTIGATOR_1890], in participants with 
COPD. 
Study design schema
Eligible participants at Screening (Visit 1) will be current or former smokers, with an 
established clinical history of COPD, receiving daily  maintenance therap y with 
tiotropi[INVESTIGATOR_496873] 3 months (no I CS or LABA maintenance therapy is allowed 
during the 3 months prior to screening), with a post- bronchodilator FEV 1of <50% 
predicted (or <80 % predicted with a documented history  of at least 2 moderate or 1 
severe [hospi[INVESTIGATOR_057]] exacerbation in the last 12 months) and a CAT score of 10. 
Participants will be requested to participate in the study  for approximately  17weeks, 
consisting of a 4 -week run-in period, 12-week treatment period and a 1- week follow -up 
period. 
Pre-screening: Details about the study  and procedures will be explained 
through the in formed consent process. The Pre-screening Visit (Visit 0 ), 
including the informed consent process, must be completed prior to an y 
protocol-required changes to a participant’s usual COPD treatment and the 
initiation of any Visit 1 procedures. Participants will continue treatment with 
their regular (i.e. pre -study) tiotropi[INVESTIGATOR_496896] -screening 
period. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
39Screening/run- in: Eligible participants will be allowed to continue their usual 
tiotropi[INVESTIGATOR_496875](Visit 
1).  On the morning of the Screening Visit participants will refrain from taking 
their morning dose of tiotropi[INVESTIGATOR_1890] . Participants who meet all of the eligibility 
criteria at Visit 1, will enter the 4 -week run-in period. 
Participants will discontinue existing tiotropi[INVESTIGATOR_496876]-
label tiotropi[INVESTIGATOR_1890] 18 mcg once dail yvia the HandiHaler plus placebo via the 
ELLIPTA. Participants will not use any  other COPD medications (except for 
those allowed per protocol). 
During the run- in period participants will also take placebo via the ELLIPTA in 
addition to open -label tiotropi[INVESTIGATOR_1890]. This will familiarise participants with the use 
of the ELLIPTA device and will help ensure participants are compliant and use 
both devices as instructed.
Participants will be provided with short-acting albuterol/salbutamol to be used 
on an as-needed basis (rescue medication) throughout the study . At Screening, 
each participant will be instructed on the proper use of the ELLIPTA and 
HandiHaler and will self-administer their first dose sof their run -in treatment 
during the Screening Visit. On the morning of the other study visits (Visit 2 
onwards), participants will refrain from taking their morning dose of stud y 
treatment until instructed to do so by  [CONTACT_6477]. 
Randomi sation/treatment: On the morning of the day  before the 
Randomisation Visit(Visit 2), participants will take their last dose of run-in 
treatment and will not use an y other COPD medications (except for those 
allowed per protocol) until the end of the study .  Rescue albuterol/salbutamol 
can be used throughout the study  as-needed but must be withheld for at least 4 
hours prior to conducting spi[INVESTIGATOR_038] .
At Visit 2 (the Randomisation Visit), participants who meet all of the 
randomisation criteria(see Section 6.3)will be randomised 1:1 to receive one 
the following double -blind study  treatments for 84 day s:
FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once dail y in the morning
+  placebo to match tiotropi[INVESTIGATOR_496897]
Tiotropi[INVESTIGATOR_1890] 18 mcg via HandiHaler once dail y in the morning
+ placebo via the ELLIPTA once dail y in the morning
Participants may  continue their study -supplied rescue albuterol/salbutamol. On 
the morning of Visits [ADDRESS_638779] dose of stud y treatment in the clinic on Day 84 
and then return to the clinic on Day  85 (Visit 5) for their final clinical 
assessments. Participants are expected on non -clinic visit day s to take their study   2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
40treatment at home in the morning at approximately  the same time each day, as 
directed b y the clinic. 
Safety/follow -up: A safety follow-up telephone contact [CONTACT_238244] (V isit 6) 
will be conducted approximately  7 days after the participant completes all of the 
protocol-defined procedures for V isit 5/End of Study  (EOS)or, if applicable, the 
Study Treatment Discontinuation Visit. A participant will be considered to have 
completed the study  when they  have completed all phases of the stud y including 
screening, run -in, the randomised treatment phase, and safety follow-up.
Participants who permanently  discontinue double -blind study  treatment are not required 
to withdraw from the study . Participants who have permanently  discontinued study  
treatment and have not withdrawn consent are encouraged to continue in the study  and
complete all remaining protocol specified clinic visits (see Section 8.1).
5.2. Number of Participants
Approximately  848participants with advanced COPD will enter the run- in,in order to 
randomise approximately [ADDRESS_638780] completed the study  if he/she has completed al l 
phases of the stud y including pre-screening, screening, run -in, the randomised treatment 
phase and the safet y follow-up. 
The end of the study  is defined as the date of the lastscheduled procedure shown in the 
Schedule of Activities (SoA)table (seeSection 2) forthe last participant in the trial 
globally.
5.4. Scientific Rationale for Study  Design
This study  will use a multi center, randomised, double -blind,double-dummy, parallel -
groupdesign. A placebo arm is not included because the primary  comparison of interest
is FF/UMEC/VI vs. tiotropi[INVESTIGATOR_496898] c onsidered appropriate to include a placebo 
arm in a study  in patients with advanced COPD. Eligible participants must have been on 
daily maintenance tiotropi[INVESTIGATOR_208461] 3 months, and those randomi sed to tiotropi[INVESTIGATOR_496899] .Although LAMA 
monotherap y in severe patients is not designated a preferred treatment option, it 
continues to be listed as a treatment option for these patients (GOLD B or D) in the 2017 
GOLD strategy  document, and is commonly  used in clinical practice .The 4-week run- in 
period is necessary  in order to assess participant compliance with and ability to use all of 
the medications together and allow sufficient time for the results of screening 
assessments to be returned to the site, in order to establish participant eligibility . 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
415.5. Dose Justification
The FF/UMEC/VI (100/62.5/25 mcg) dose was selected based on the doses that have 
beenlicensedfor COPD for the FF/VI (100/25 mcg) and UMEC/VI (62.5/25mcg) dual 
combinations through extensive studies in the mono and dual therap y programmes. It is 
the dose which is currently  under regulatory  review based on the Phase IIIa 
FF/UMEC/VI registration programme.
The dose selected for tiotropi[INVESTIGATOR_1890] (18mcg, once daily ) is the dose licensed in the US for 
use in COPD .
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollm ent criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply:
1.Informed consent: capable of giving signed informed consent prior to study  start
which includes compliance with the requirements and restrictions listed in the 
informed consent form (ICF) and in this protocol.
2.Type of participant : Outpatient.
3.Age: Participants 40 years of age or older at Screening (Visit 1).
4.Gender: Male or female participants.
Female participant s: 
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and 
at least one of the following conditions applies:
Not a woman of childbearing potential (WOCBP) 
OR
A WOCBP who agrees to follow the cont raceptive guidance in 
Appendix 3during the treatment period and until the safet y follow-up 
contact[CONTACT_496959].
5.COPD Diagnosis : An established clinical history  of COPD in acc ordance with the
definition by  [CONTACT_496960] y/European Respi[INVESTIGATOR_21618] [ Celli, 
2004].
6.Smoking History : Current or former cigarette smokers with a history  of cigarette
smoking of ≥10pack-years at Screening (Visit 1) [number of pack y ears = (number of  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
42cigarettes per day  / 20) x number of y ears smoked (e.g., 20 cigarettes per day  for10 
years, or 10 cigarettes per day  for 20 years)]. Previous smokers are defined as those 
who have stopped smoking for at least 6 months p rior to Visit 1. Note : Pi[INVESTIGATOR_496900]/or 
cigar use cannot be used to calculate pack -year history .
7.Severity of COPD symptoms: A score of ≥[ADDRESS_638781] (CAT) 
at Screening (Visit 1).
8.Severity of Disease: 
Participants must demonstrate at Screening:
oa post-bronchodilator FEV 1<50% predicted normal
OR
oa post-bronchodilator FEV 1<80% predicted normal and a documen ted 
historyof ≥2 moderate exacerbations or one severe (hospi[INVESTIGATOR_057]) 
exacerbation in the previous [ADDRESS_638782] albuterol/salbutamol FEV 1/forced vital 
capacity (FVC) ratio of <0.70 at screening.
Note: Percent predicted will be calculated using the European Respi[INVESTIGATOR_496901] [ Quanjer, 2012].
Note: A documented history of a COPD exacerbation (e.g., medical record 
verification) is a medical re cord of worsening COPD symptoms that required 
systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or 
hospi[INVESTIGATOR_059] (for a severe exacerbation). Prior use of antibiotics alone does not 
qualify as an exacerbation history unless t he use was associated with treatment of 
worsening symptoms of COPD, such as increased dyspnoea, sputum volume, or 
sputum purulence (colour). Participant verbal reports are not acceptable.
9.Existing COPD maintenance treatment: participant must have beenreceiving 
dailymaintenance treatment with tiotropi[INVESTIGATOR_496902] (via the Handihaler or Respi[INVESTIGATOR_96862] ) 
for their COPD for at least 3 months prior to Screening.
Note: Participants takingonly as-neededtiotropi[INVESTIGATOR_496903].
6.2. Exclusion Criteria
Participants are excluded from the study  if any of the following criteria apply :
1.Pregnancy: Women who are pregnant or lactating or are planning on becoming
pregnant during the study.
2.Asthma: Participants with a current diagnosis of asthma. ( Participants with a prior 
historyof asthma are eligible if they  have a current diagnosis of COPD). 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
433.α1-antitrypsin deficiency : Participants with α1-antitrypsin deficiency  as the 
underlyingcause of COPD.
4.Other respi[INVESTIGATOR_17744]: Participants with active tuberculosis, lung cancer, and 
clinicallysignificant: bronchiectasis, sarcoidosis, lung fibrosis, pulmonary  
hypertension, interstitial lung disease or other active pulmonary  diseases. 
5.Lung resection : Participants who have undergone lung volume reduction surgery  
within the 12 months prior to Screening.
6.Risk Factors for Pneumonia : immune suppression ( e.g.advanced human 
immunodeficiency  virus [HIV]with high viral load and low CD4 count, lupus on 
immunosuppressants) thatin the opi[INVESTIGATOR_496904] ( e.g. neurological disorders a ffecting 
control of the upper airway, such as Parkinson ’s Disease, M yasthenia Gravis).
Participant s at potentially high risk for pneumonia (e.g. very low body mass index 
[BMI], severely malnourished, or very low FEV 1) will only  be included at the 
discretion of the Investigator .
7.Pneumonia and/or moderate or severe COPD exacerbation that has not resolved
at least [ADDRESS_638783] dose of
oral/systemic corticosteroids (if applicable). 
8.Respi[INVESTIGATOR_496905] [ADDRESS_638784] x -ray: Chest x-ray (posteroanterior and lateral) reveals evidence of
pneumonia or a clinically significant abnormality  not believed to be due to the
presence of COPD, or another c ondition that would hinder the ability  to detect an
infiltrate on chest x-ray(e.g. significant cardiomegal y, pleural effusion or scarring). 
All participants will have a chest x -ray at Screening Visit 1 (or historical radiograph 
or computerized tomography  [CT]scan obtained within 3 months prior to screening).   
Note: Participants who have experienced pneumonia and/or moderate or severe 
COPD exacerbations within [ADDRESS_638785] 
pneumonia/exacerbation chest X -ray or have a chest X -ray conducted at Screening.
For sites in [LOCATION_013]: If a chest x -ray (or CT scan) within 3 months prior to Screening 
(Visit 1) is not available, approval to conduct a diagnostic chest x -ray willneed to be 
obtained from the Federal Office for Radiation Prote ction (BfS).
10.Other diseases/abnormalities : Participants with historical or current evidence of
clinically significant cardiovascular, neurological, psy chiatric, renal, hepatic,
immunological, gastrointestinal, urogenital, nervous sy stem, musculoskeletal, skin,
sensory, endocrine (including uncontrolled diabetes or thy roid disease) or
haematological abnormalities that are uncontrolled. Significant is defined as any
disease that, in the opi[INVESTIGATOR_689] , would put the safet y of the participant
atrisk through participation, or which would affect the efficacy  or safety analysis if 
thedisease/condition exacerbated during the stud y. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10326].Unstable liver disease : ALT >2xULN; and bilirubin >1.5x ULN (isolated bilirubin 
>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
Current active liver or biliary disease (with the exception of Gilbert’s syndrome or 
asymptomatic gallstones or otherwise stable chronic liver disease per investigator 
assessment). 
NOTES: 
Stable chronic liver disease should generally be defined by [CONTACT_387054], encephalopath y, coagulopathy , hypoalbuminaemia, oesophageal or 
gastric varices, or persistent jaundice, or cirrhosis.
Chronic stable hepatitis B and C (e.g., presence of hepatitis B surface antigen 
(HBsAg) or positive hepatitis C antibody test result at screening or within [ADDRESS_638786] dose of study treatment) are acceptable if participant
otherwise meets entry  criteria.
12.Unstable or life threatening cardiac disease: Participants with any of the following 
atScreening (Visit 1) would be excluded
Myocardial infarction or unstable angina in the last 6 months
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 3
months
[LOCATION_001] Heart Association ( NYHA)Class IV He art failure
13.Abnormal and clinicall y significant 12- lead ECG finding at Visit 1
The Investigator will determine the clinical significance of each abnormal ECG 
finding in relation to the participant’s medical history  and exclude participants 
who would be at undue risk by  [CONTACT_19212]. 
An abnormal and clinically  significant finding that would preclude a participant
from entering the trial is defined as a 12 -lead ECG tracing that is interpreted at, 
but not limited to, any  of the following:
i.Atrialfibrillation ( AF)with rapid ventricular rate >120 beats per 
minute (BPM)
ii.Sustained and non -sustained ventricular tach ycardia(VT)
iii.Second degree heart block Mobitz ty pe II and third degree heart 
block (unless pacemaker or defibrillator had been inserted)
iv.QT interval corrected for heart rate ≥500 msec in participants with 
QRS <120 msec and QTcF ≥530 msec in participants with QRS 
≥120 msec
14.Contraindications : A history  of allergy  or hypersensitivity  to any corticosteroid,
anticholinergic/m uscarinic receptor antagonist, β 2-agonist, lactose/milk protein or
magnesium stearate or a medical condition such as narrow -angle glaucoma, prostatic
hypertrophy  or bladder neck obstruction that, in the opi[INVESTIGATOR_689] ,
contraindicates stud y participation. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10327].Cancer: Participants with carcinoma that has not been in complete remission for at 
least3years. Participants who have had carcinoma in situ of the cervix, squamous 
cellcarcinoma and basal cell carcinoma of the skin would not be excluded based on 
the 3year waiting period if the participant has been considered cured b y treatment.
16.Oxygen therapy : Use of long -term oxygen therapy  (LTOT) described as resting
oxygen therap y >3L/min (Ox ygen use ≤3L/min flow is not exclusionary .)
17.Medication prior to spi[INVESTIGATOR_038] : Participants who are medically  unable to withhold
their albuterol/salbutamol for the 4- hour period required prior to spi[INVESTIGATOR_496906] y visit.
18.Pulmonary rehabilitation : Participants who have participated in the acute phase of a 
Pulmonary  Rehabilitation Programme within 4 weeks prior to screening or 
participants who plan to enter the acute phase of a Pulmonary  Rehabilitation 
Programme during the study . Participants who are in t he maintenance phase of a 
Pulmonary  Rehabilitation Programme are not excluded.
19.Drug/alcohol abuse : Participants with a known or suspected history  of alcohol or 
drugabuse within the last 2 y ears.
20.Non-compliance : Participants at risk of non- compliance, or u nable to comply  with 
thestudy procedures. Any  infirmity, disability, or geographic location that would 
limitcompliance for scheduled visits.
21.Questionable validity of consent : Participants with a history  of psychiatric disease,
intellectual deficiency , poor motivation or other conditions that will limit the validity
of informed consent to participate in the stud y.
22.Affiliation with Investigator site: study Investigator s, sub-Investigator s, study
coordinators, emplo yees of a participating Investigator or study site, or immediate
family members of the aforementioned that is involved with this study .
23.Inability to read : In the opi[INVESTIGATOR_689] , any participant who is unable to
read and/or would not be able to complete stud y related materials.
24.Medicati on prior to screening: See Table 4inSection 7.7.2forthe list of 
medications and associated time intervals prior to Visit 1.
Medication No use within the following time intervals prior 
to Screening 
Inhaled short- acting anticholinergics 6 hrs
Inhaled short- acting beta 2 agonists1 ≥4 hrs
Inhaled short- acting anticholinergics + short -acting 
beta agonist combination6 hrs 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
46Medication No use within the following time intervals prior 
to Screening 
Inhaled Corticosteroids (ICS)
Use as main tenance treatment in the 3 months prior 
to Visit 1 is not permitted.
Maintenance treatment is defined as use for ≥14 
consecutive days (at any time in the 3 months prior 
to Visit 1).Inhaled Corticosteroids (ICS)/Inhaled long- acting 
beta 2-agonist (LABALAB A) combinations 
(eg.fluticasone/salmeterol, mometasone 
furoate/formoterol fumarate, budesonide/formoterol 
fumarate; fluticasone furoate/vilanterol
Phosphodiesterase 4 (PDE4) inhibitors (roflumilast)
LABA (e.g., indacaterol, olodaterol)
Long acting mu scarinic antagonists2(LAMA) (eg 
umeclidinium, aclidinium, glycopyrronium)
LAMA/LABA combinations
Theophyllines
Sodium cromoglycate and nedocromil sodium
Anti-leukotrienes
Long term antibiotic therapy Participants receiving antibiotics for long t erm 
therapy are not eligible for the study.
(Antibiotics are allowed for the short term treatment 
(≤14 days) of an exacerbation or for short term 
treatment ( ≤14 days) of other acute infections during 
the study)
Systemic, oral, parenteral corticosteroids 30 days
(During the study oral/systemic corticosteroids may 
be used for ≤14 days to treat COPD 
exacerbations/pneumonia) 
Intra- articular injections are allowed
Any other investigational drug 30 days or 5 half lives whichever is longer. 
1(rescue albutero l/salbutamol will be provided and is permitted during the study)                               
[ADDRESS_638787] 3 months prior to screening. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
476.3. Randomisation Criteria
At the end of the run -in period (Visit 2), s tudy participants must fulfil the following 
additional criteria in order to be randomised into the study  and enter the treatment period.
1.CAT score at Randomisation (Visit 2)
Participants with CAT score <10 at R andomisation (Visit 2) will be excluded.
2.Compliance with run -in study medication
Compliance with each run-in study medication will be assessed by  [CONTACT_3786], an y participant <80% or >120 % compliant with either of the two 
inhalers (ELLIPTA or Handihaler) will be excluded.
3.COPD exacerbation or pneumonia
Participants that experiences a moderate or a severe COPD exacerbation or 
pneumonia during the run -in period will be excluded. 
4.Changes in COPD med ication
Any participant that requires a change in COPD medication from tiotropi[INVESTIGATOR_1890] 
(18mcg) and rescue medication (albuterol/salbutamol) during the run -in period 
will be excluded. This includes a temporary change in COPD medication. 
6.4. Lifestyle Restrictions
Participant s should refrain from smoking for [ADDRESS_638788].
Participant s should abstain from drinking beverages with high levels of caffeine such 
as tea and coffee for [ADDRESS_638789] .
6.5. Pre-screening/ Screening/Run-in/Randomisation Failures
A participant will be assigned a participant nu mber at the time the informed consent is 
signed at Visit 0.
The study  site will be responsible for reporting pre -screen failures. The following 
information will be collected in the electronic case report form ( eCRF)for participants 
who are pre -screen fail ures: demographic information including race, age and gender; 
participant number; SAE information onlyfor any SAE considered to be related to study  
participation.
A minimal set of information is required to ensure transparent reporting of screen ing/run-
in/randomisation failure participant s to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory  
authorities. Minimal information includes demography , screening/run-in/randomisation
failure details, eligibility  criteria, and any  SAEs. Further details are provided in the study - 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
48specific eCRF completion guidelines. For the purposes of this study , pre-screening 
failures, screening failures, run-in failures and randomisation failures will be d efined as 
follows:
Pre-screening failures: those participants that sign the informed consent document but 
do not have a Visit 1 (Screening) procedure.
Screening failures: those participants that complete at least Visit 1 (Screening) 
procedure but do not en ter the run -in period. A participant who completes Visit [ADDRESS_638790] entered the run -in period.
Run-in failures: those participants that enter the run- in period but do not have any Visit 
2 (Randomisation) procedures , orthose participants that complete at least one Visit 2 
(Randomisation) procedure but do not enter the double -blind study  treatment period. Any  
participant who completed the run -in period and meets the randomisation criteria and is 
dispensed the double -blind study  treatment at Visit [ADDRESS_638791] entered the 
treatment period.
7. TREATMENTS
Study treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo,or medical device (s)intended to be administered to a study  participants
according to the stud y protocol.
7.1. Treatment Groups and Duration
Participants who meet all the eligibility  criteria and who have successfull y completed all 
protocol procedures at Screening will enter the 4-weekrun-in period and will take open-
label tiotropi[INVESTIGATOR_1890] 18 mcg via the HandiHaler once dail y plus placebo via the ELLIPTA . 
Following the run -in period, participants who meet randomisation criteria will be 
randomised (1:1) to one of the following double -blind, double-dummytreatment groups
for 84 day s:
Either:
FF/UMEC/VI 100/62.5/25 mcg via the ELLIPTA once dail y in the morning
+  placebo to match tiotropi[INVESTIGATOR_496878],
Tiotropi[INVESTIGATOR_1890] 18 mcg via HandiHaler once dail y in the mor ning
+ placebo via the ELLIPTA once dail y in the morning
The ELLIPTA contains 30 doses (FF/UMEC/VI or placebo) and participants will be
instructed to administer one dose from their ELLIPTA once dail y in the morning. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
49Tiotropi[INVESTIGATOR_496879] : Contents of 1 capsule (18 mcg) inhaled once dail y 
using HandiHaler device. Note: To ensure drug delivery, two inhalations of the contents 
of each capsule should be performed.
Descriptions of the stud y treatments administered via the ELLIPTA and the Handihaler 
areprovided in Table 2and Table 3respectivel y. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
50Table 2Description of FF/UMEC/VI Inhalation Powder in ELLIPTA ™
FF/UMEC/VI First strip Second strip 
GW685698 blended with 
lactoseGW642444 and [COMPANY_004]573719 
blended with lactose and 
magnesium stearate
Dosage Form ELLIPTA with 30 doses (2 strips with 30 blisters per strip)
Unit Dose 
Strengths 100mcg per blister25 mcg per blister GW642444, 62.[ADDRESS_638792] strip Second strip
Lactose Lactose/Magnesium Stearate
Dosage Form ELLIPTA with 30 doses ( 2stripswith 30 blisters per strip)
Unit Dose 
StrengthsNA Dry white powder
Physical 
descriptionDry white powder NA
Route of 
AdministrationInhaled
Table 3Description of Tiotropi[INVESTIGATOR_496907] 18mcg HandiHaler
Dosage form Capsule
Unit dose strength 18mcg
Physical description Hard gelatin capsule containing 18mcg 
tiotropi[INVESTIGATOR_496908] 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
517.1.1. Medical Devices
The [COMPANY_004] ELLIPTA medical devic e will beprovided for use in this study .
The other medical device (not manufactured b y or for [COMPANY_004] provided )for use in this
study is the Handihaler .
[COMPANY_004] medical device incidents, including those resulting from malfunctions of the
device, must be detected, documented, and reported by  [CONTACT_496961]. (see Section 9.2.10).
7.2. Dose Modification
No dose modifications are planned for this study .
7.3. Method of Treatment A ssignment
Participants will be assigned to study  treatment in accordance with the randomisation 
schedule. The randomisation code will be generated by [CONTACT_2329] a validated computerised 
system. Participants will be randomised using an Interactive Web Response Sy stem 
(IWRS). The stud y will use central -based randomisation to allocate treatments. Once a 
randomisation number is assigned to a participant it cannot be reassigned to any  other 
participantin the study . 
7.4. Blinding
This will be a double- blindstudy and the following will appl y. 
The Investigator or treating phy sician may  unblind a participant ’s treatment 
assignment only in the case of an emergency OR in the event of a serious 
medical c ondition when knowledge of the study  treatment is essential for the 
appropriate clinical management or welfare of the participant as judged b y the 
Investigator . 
Investigator s have direct access to the participant ’s individual study  treatment. 
It is prefe rred (but not required) that the Investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the participant ’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the Investigator must 
notify [COMPANY_004] within 24 hours after unblinding, but without revealing the treatment 
assignment of the unblinded participant , unless that information is important for 
the safety of participant s currentl y in the stud y. 
The date and event or c ondition which led to the unblinding (i.e. the primary 
reason)will be recorded in source documentation and in the eCRF. 
Should a participant’s treatment assignment be unblinded then the participant may  
continue the assigned study  treatment and be followe d-up as per protocol until the 
completion of the Safety Follow-up assessments . 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
52[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  participant with an SAE. If the SAE requires that an 
expedited regul atory report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant ’s treatment assignment, may  be sent to Investigator s in 
accordance with local regulations and/or [COMPANY_004] policy. Participants will not be withdrawn 
from the study.
Masking of tiotropi[INVESTIGATOR_496909]-dummy design for dosing, whereby [CONTACT_3445] s will be 
given twoinhalers (ELLIPTA and Handihaler) . All participants andsite personnel 
involved in efficacy  andsafety assessments will be blinded to assigned treatment during
the study. Tiotropi[INVESTIGATOR_496910]. This study  has aparallel-group design which ensures the capsuletype will be
consistent for e ach participantfor the duration of the study.In addition, tiotropi[INVESTIGATOR_496911]. Both the tiotropi[INVESTIGATOR_496912] w ill becovered with opaque over -labels with theintent of hiding the 
informatio n on the tiotropi[INVESTIGATOR_496913]. The HandiHaler dry powder inhalers w ill be 
covered with labels to mask identify ing marks on the inhaler. Investigator and site 
personnel involved in efficacy  and safet y assessments will be instructed not be present
when a par ticipant administers his/her study  medication at clinic visits, to guard against 
the possibility  of personnel involved in the collection of efficacy  and safety  data,
identifying thecapsules removed from the blisters . Sites are required to have study  
treatment dose d, dispensed and accounted for by  [CONTACT_496962].
7.5. Preparation/Handling/Storage/A ccountability
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study  treatment received and any  discrepancies are 
reported and resolved before use of the stud y treatment.
Only participants enrolled in the study  may receive study  treatment and only  authorized 
site staff may  supply or adminis ter study treatment. All study  treatments must be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the Investigator and 
authorized site staff.
The Investigator , institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
Further guidanc e and information for the final disposition of unused stud y treatment are 
provided in the Study Reference Manual ( SRM). 
Under normal conditions of handling and administration, study treatment is not expected 
to pose significant safet y risks to site staff. Take adequate precautions to avoid direct ey e 
or skin contact [CONTACT_23968]. I n the case of unintentional 
occupations exposure notify  the monitor, Medical Monitor and/or [COMPANY_004] study  contact. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
53A Material Safety Data Sheet (MSDS) desc ribing occupational hazards and 
recommended handling precautions will be provided to the Investigator , where is this 
required b y local laws, or is available upon request from [COMPANY_004] .
7.6. Treatment Compliance
When participant sare dosed at the site, they  will receive study treatment under medical 
supervision.  The date and time of each dose administered in the clinic will be recorded in 
the eCRF .  The dose of study  treatment and study  participant identification will be 
confirmed at the time of dosing b y a member of the study site staff.  
When participant s self-administer study  treatment(s) at home , compliance with study  
treatment will be assessed through query ing the participant during the site visits and 
recording the number of doses remaining in the ELLIPTA and the number of capsules of 
tiotropi[INVESTIGATOR_1893] (or matching placebo) dispensed and taken b y each participant, in the 
eCRF (see SRM for details).
Participants who are non -compliant should be re -educated on the importance of treatment 
compliance. Every  effort will be made to keep participants in the study  and to re-educate 
those participants who continue to be non- compliant.  Participants who continue to be 
non-compliant after multiple visit assessments may  be permanently  discontinued from 
study treatment afterconsultation with the [COMPANY_004] clinical team.
7.7. Concomitant Therapy
All COPD medications used within 3 months prior to screening and during the run-in and 
study treatment periods (including the post -treatment period) should be recorded in the 
eCRF. 
All non-COPD medications taken during the study (after randomisation including post -
treatment) and an y changes to concomitant medications will be recorded in the eCRF.  
The minimum requirement is that thedrug name , reason for use , dose(including unit) , 
frequency , route and the dates of administration are to be recorded.
Note: Study provided albuterol/salbutamol should not be recorded in the eCRF however 
non-study supplied albuterol/salbutamol will be recorded in the eCRF.   
Medications initiated after completion of the randomi sed treatment phase of the study  
(Visit 4) or started after discontinuation of study  treatment must be recorded in the eCRF 
up to the safet y follow-up (Visit6). 
7.7.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Permitted COPD Medications
The following COPD medications are permitted during the run-in and study treatment
periods:  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
54Study supplied albuterol/salbutamol metered dose inhaler ( MDI)or nebules (must be 
withheld for at least 4 hours prior to spi[INVESTIGATOR_496914])
Mucolytics such as acet ylcysteine
Long term ox ygen therapy.  (To be eligible to enter the study at Visit 1, participants
who are on LTOT must be using at a flow rate of ≤3 liters/minute at rest.  However, 
oxygen therap y may be adjusted as deemed medically  necessary  at any time during 
the run-in or treatment phases of the study ). Oxygen therapy must be captured on the 
concomitant medication page of the eCRF.  Supplemental oxy gen is recommended 
for participant s who exhibit oxy hemoglobin desaturation with rest or exertion ( e.g.
SaO2 ≤88 %)
Maintenance phase of pulmonary  rehabilitation treatment ( participants are not 
allowed to initiate treatment during the stud y)
The following COPD medications are permitted during the study treatment period: 
Oral or injectable corticosteroids (short course ≤14 days) only for the short term 
treatment of COPD exacerbations and/or pneumonia
Antibiotics (short course ≤14 days) for the short term treatment of COPD 
exacerbations and/or pneumonia
Any COPD medication deemed medically  necessary  for the short term tr eatment 
(≤14days) of a moderate/severe COPD exacerbation or pneumonia
[IP_ADDRESS]. Permitted Non -COPD Medications
The following non-COPD medications are permitted during the run-in and study 
treatment periods:
Medications for rhinitis ( e.g. intranasal corticosteroids, antihistamines, cromoly n, 
nedocromil, nasal decongestants)
Topi[INVESTIGATOR_238426]
Localized corticosteroid injections (e.g. intra -articular and epi[INVESTIGATOR_13873])
Vaccinations (Influenza vaccine, Pneumonia vaccine, Shingles vaccine, etc.) 
(Administr ation of influenza and pneumonia vaccines should be considered based 
on clinical discretion of the Investigator and local/national guidelines. Current 
influenza vaccines and pneumonia vaccines will be captured on the concomitant 
medication pages of the eCR F)
Allergy immunotherapy
Antibiotics for short -term treatment ( ≤14 days) of acute infections. (Long term 
treatment with antibiotics is not allowed) 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
55Systemic and ophthalmic beta -blockers. (Administer with caution as s ystemic 
beta-blockers block the pulmonar y effect of beta- agonists, and may  produce severe 
bronchospasm in participant s with reversible obstructive airway s disease. 
Cardioselective beta -blockers should be considered, although they  also shoul d be 
administered with caution)
Smoking cessation treatments 
Cough suppressants 
Tricyclic antidepressants and monoamine oxidase inhibitors (MAOI s). (Administer 
with extreme caution as they  may potentiate the effects of beta -agonists on the 
cardiovascular s ystem, including QT interval corrected for heart rate [ QTc]
prolongation)
Diuretics.(Caution is advised in the co -administration of beta -agonists with non-
potassium sparing diuretics as this may  result in electrocardiogram [ ECG]changes 
and/or hy pokalemia )
Use of positive airway  pressure for sleep apnea
Oralmuscarinic antagonists for the treatment of overactive bladder are permitted 
but should be used with caution as they  may exacerbate medical conditions that are 
contraindicated for anticholinergics (e.g., narrow angle glaucoma a nd bladder 
outflow obstruction)
Cytochrome P450 (CYP)3A4 inhibitors. (Caution should be exercised when 
considering the coadministration of long- term ketoconazole and other known 
strong CYP3A4 inhibitors (e.g., ritonavir, clarithromy cin, conivaptan, indinavir, 
itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, saquinavir, telithromy cin, 
troleandomycin, voriconazole) because increased sy stemic corticosteroid and 
increased cardiovascular adverse effects may  occur)
7.7.2. Prohibited Medications and Non-Drug Therapi[INVESTIGATOR_417438] 4is not permitted during the study .
Table 4Concomitant Medications
Medication Prohibited during the randomi sed treatment period
Inhaled short- acting anticholinergics
Inhaled short- acting beta2 agonists1
Inhaled short- acting anticholinergic/short -acting beta2 -agonist combination products
Inhaled corticosteroids (ICS) 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
56Medication Prohibited during the randomi sed treatment period
Inhaled corticosteroids (ICS)/Inhaled long -acting beta 2-agonist (LABA) combinations 
(eg.fluticasone/salmeterol, mometasone furo ate/formoterol fumarate, budesonide/formoterol fumarate; 
fluticasone furoate/vilanterol
Phosphodiesterase 4 (PDE4) inhibitors (roflumilast)
LABA (e.g., indacaterol, olodaterol, salmeterol etc. )
Other LAMAs (aclidinium, glycopyrronium, umeclidinium etc. )
LAMA/LABA combinations
Theophyllines
Sodium cromoglycate and nedocromil sodium
Anti-leukotrienes
Long term antibiotic therapy2
Systemic, oral, parenteral corticosteroids 3
Any other investigational drug
1 (rescue albuterol/salbutamol will be prov ided and is permitted during the study)       
2(Antibiotics are allowed for the short term treatment ( ≤14 days) of an exacerbation or for short term 
treatment ( ≤14 days) of other acute infections during the study)
3(During the study oral/systemic cortico steroids may be used for ≤14 days to treat COPD 
exacerbations/pneumonia). Intra-articular injections are allowed .
Note: Topi[INVESTIGATOR_238426], and localized corticosteroid injections 
(intra-articular and epi[INVESTIGATOR_13873]) are allowed.
NOTE:All COPD medications (except for rescue albuterol/salbutamol, mucolytics and 
oxygen) are prohibited during the run-in and randomi sed treatment period s of the study 
except during the treatment of a moderate/severe COPD exacerbation or pneumonia. In 
the event of a n exacerbation or pneumonia, sites should attempt to follow protocol 
treatment guidelines, however, treatment with any medication that the health care 
provider deems necessary is allowed.  Caution is advised in using a LABA or LAMA to 
treat a participant currently taking study treatment as these additional medications may 
increase the risk o f overdose. If necessary the Investigator or other health care 
personnel may stop the participant’s study treatment temporarily (≤14 days) in order to 
treat the COPD ex acerbation or pneumonia.  Participants who require more than two 
consecutive 14 day courses of treatment (i.e. antibiotics or corticosteroids) should be 
evaluated for their continuation on study treatment by [CONTACT_496963].
The Medical Monitor should be contact[CONTACT_43205] y questions regarding 
concomitant or prior therapy . 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638793] -
study care of the participant ’s medical condition.
At the end of the treatment period ( Visit 5), or after study  treatment Discontinuation 
Visit, or withdrawal from study , participants can resume conventional COPD therap y as 
prescribed b y the Investigator .  Post-treatment concomitant medication should be entered 
into the eCRF until the safet y follow-up visit for participants that successfully  complete 
Visit [ADDRESS_638794] -treatment concomitant medication 
should be entered into the eCRF until they  complete the visit/telephon e contact [CONTACT_496964] 6 date.
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
Participants that permanently  stop study  treatment should return to the clinic as soon as 
possible, in order to complete the Study  Treatment Discontinuation Visit. The evaluations 
and procedures to be completed are outlined in the SoA (Section 2). 
Participants that discontinue study  treatment are encouraged to remain in the study  and 
every effort should b e made by  [CONTACT_737]/staff to keep the participant in the study , 
to collect important efficacyand safety data by [CONTACT_24646]. Ideally, participants 
should return to the clinic to complete Visit 5, to collect important spi[INVESTIGATOR_44049], 
however, if this isn’t possible, this visit should also be completed by  [CONTACT_756]. A safety  
follow-up phone call (Visit 6) should also be conducted 7 day s after Visit 5. 
The Investigator/site staff should contact [CONTACT_496965]:
SAEs 
AEs assessed as related to study  participation
AEs resulting in withdrawal from the stud y
COPD exacerbations 
Concomitant medication
Spi[INVESTIGATOR_038]  (Visit 5 only , if participant consents)
Participant s have the right to discontinue study  treatment before the end of the study . A 
participant may  also be asked to discontinue study treatment at the Investigator ’s 
discretion.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
58A participant may  be withdrawn from study  treatment at any  time. A reason for 
premature discontinuation of study  treatment (e.g., AE, lack of efficacy , protocol 
deviation, Investigator discretion, consent withdrawn etc.) must be captured in the 
eCRF.Protocol defined criteriafor discontinuation of study  treatment
A participant must be permanently  discontinued from study treatment if any of the 
following stoppi[INVESTIGATOR_23893]: 
Liver chemistry stoppi[INVESTIGATOR_496915](in alignment wit h the 
FDA premarketing clinical liver safet y guidance). These protocol guidelines are in 
alignment with FDA premarketing clinical liver safet y guidance: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered by  
[CONTACT_260058] a participant meets one of the conditions outlined in the 
algorithm or if the Investigator believes that it is in the best interest of the 
participant.
Liver Safet y Algorithms and Required Actions and Follow up Assessments can be 
found inAppendix 4.
Pregnancy: Positive urine pregnancy  test.
QTc Stoppi[INVESTIGATOR_2121]: 
Details on performing ECG assessments can be found in Section 9.4.3
The sameQT correction formula must be used for each individual participant
to determine eligibility  for and discontinuation from the study .  This formula 
may not be changed or substituted once the participant has been enrolled.
Safety ECGs and other non -protocol specified ECGs are an exception.
For example, if a participant is eligible for the protocol based on QT 
interval corrected for heart rate b y Bazett’s formula (QTcB), then QTcB 
must be used for discontinuation of this in dividual participant as well.
Once the QT correction formula has been chosen for a participant ’s 
eligibility , the same formula must continue to be used for that participant
for all QTc data being collected for data analysis .  
The QTc should be based on averaged QTc values of triplicate 
electrocardiograms obtained over a brief (e.g., 5-10 minute) recording period.
For this study , the following QTc stoppi[INVESTIGATOR_496916] :
an increase in QTc b y > 60 msec from baseline or
development of a QTc > 530 msec (based on an average of triplicate 
ECGs) 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
59NOTE: These criteria should be based on the average QTc value of triplicate 
ECGs.  For example, if an ECG demonstrates a prolonged QT interval, two 
more ECGs will be obtained over a brief period and then the averaged QTc 
value of the three ECGs will be used to determine whether the participant should 
be discontinued from the study .
See the SoA for data to be collected at the time of treatment discontinuation and follow -
up and for any further evaluations that need to be completed.
8.1.1. Rechallenge
[IP_ADDRESS]. Study Treatment Restart or Rechallenge
Study treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_496917].
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at any time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the Investigator for safety , behavioral, 
compliance or administrative reasons.
If the participant withdraws co nsent for disclosure of future information, the sponsor may  
retain and continue to use an y data collected before such a withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  samples 
taken and not tested, an d the Investigator must document this in the site study  records.
In the event of earl y withdrawal from the study, every  effort should be made to have the 
participant to return to the clinic for a Study Treatment Discontinuation Visitand Safety  
Follow-up,and to return all study  related materials. Assessments to be performed during 
the Study  Treatment Discontinuation Visit and the Safet y Follow-up contact [CONTACT_496966] (Section 2).
Participants that have previously  discontinued study  treatment (and have already  
completed the Study  Treatment Discontinuation Visi t) but then decide they no longer 
wish to participate in the study , may withdraw from the study  by [CONTACT_116332] b y 
telephone. 
If the participant withdraws from the study  at least [ADDRESS_638795] (Visit 6) can be 
conducted at the time the participant notifies the site of their intentio n to withdraw from 
the study. Alternativel y, the safet y follow-up contact [CONTACT_496967] [ADDRESS_638796] be taken if a participant fails to return to the clinic for a 
required stud y visit: 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
60The site must attempt t o contact [CONTACT_43207]/or should continue in the stud y.
Before a participant is deemed lost to follow up, the Investigator or designee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant ’s last known 
mailingaddress or local equivalent methods). These contact [CONTACT_19425] ’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of l ost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study procedures and their timing are summarized in the SoA (Section 2). 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with th e sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The Investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for sc reening failure, as applicable.
No study related procedures may be performed until the informed consent form 
has been signed by [CONTACT_2299]. A Pre-Screening visit (Visit 0) is required in 
order to administer the informed consent befor e any changes are made to the 
participant’s current medical regimen.  Selection and modification of the 
participant’s medications prior to study  participation is based on the physician’s 
judgment according to sound medical practice, principles, and each pa rticipant’s 
needs.  A participant’s treatment must not be changed merel y for the purpose of 
enabling the participant’s participation in the study.
During the P re-Screening visit (V isit 0) the following information will be captured in the 
eCRF for each part icipant: 
Demographic information including race, age and gender
Participant number
Register visit in IWRS
The additional following critical baseline assessments will be conducted at Screening 
(Visit 1): 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
61Medical history  including COPD history  (comprised of COPD type [emphy sema 
and/or chronic bronchitis]), smoking history , COPD exacerbations history , 
smoking status and previous and/or current medical conditions.
Demograph y
Concomitant Medications
COPD exacerbation assessment (documented history  of exacerbati on(s))
Cardiovascular medical history /risk factors
Inclusion/Exclusion criteria 
Physical examination (including orophary ngeal examination)
Pulse rate, blood pressure me asurements
12-lead ECG
Pre-and post-albuterol/salbutamol spi[INVESTIGATOR_038] (reversibility )
SAE assessment (if related to study  participation)
Chest X-Ray or (historical radiograph obtained within 3 months prior to 
screening)
Laboratory  assessments (chemistry  and hematology , hepatitis and pregnancy  
testing)
CAT
Administer and dispense run- in study treatment
Inaddition the following procedures must be completed at Screening ( Visit 1):
Smoking cessation counseling
Register visit in IWRS
Dispense albuterol/salbutamol
9.1. Efficacy  Assessments
The timings of all efficacy  assessments are specified in the S oA (Section 2).
9.1.1. Spi[INVESTIGATOR_496918] y 
(ATS)[Miller, 2005].  All sites will use standardise d spi[INVESTIGATOR_496919].  All participant s will have spi[INVESTIGATOR_496920]. For FEV 1and FVC 
determinations, at lea st 3 acceptable spi[INVESTIGATOR_496921] (with no more than 8) should be 
obtained.  Acceptable spi[INVESTIGATOR_496922] a satisfactory  start of test and end of 
test (e.g. a plateau in the volume -time curve) and be free from artifacts due to cough,  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
62early termination, poor effort, obstructed mouthpi[INVESTIGATOR_13959], equipment malfunction, or other 
reasons [Miller, 2005].
The largest FEV 1and FVC from the [ADDRESS_638797] be performed as follows:
Started approximately  between 6:00AM and 11:00AM.
If applicable, after completing the health outcomes assessments ( CATshould be 
administered first followed by [CONTACT_312495]-C)
After withholding albuterol/salbutamol for 4 hours. 
At Screening(Visit 1), before the morning dose of their usual COPD medication .  
At Randomisation (Visit 2) and all treatment visits, before the morning dose of study  
treatment .
Participant s should refrain from smoking for [ADDRESS_638798].
Participant s should abstain from drinking beverages with high levels of caffeine such 
as tea and coffee for [ADDRESS_638799] of spi[INVESTIGATOR_496923] t he 
SRM.
[IP_ADDRESS]. Reversibility
At Visit 1, both pre -and post-albuterol/salbutamol spi[INVESTIGATOR_496924].  Post -
albuterol/salbutamol FEV 1and FEV 1/FVC findings will be used to determine participant
eligibility .  
Reversibility  testing will be completed as fol lows:  Following pre -albuterol/salbutamol 
spi[INVESTIGATOR_038]  (three acceptable spi[INVESTIGATOR_496921]), the participant will self-administer 4 
puffs of albuterol/salbutamol MDI  using a spacer/valved -holding chamber.  Three 
acceptable spi[INVESTIGATOR_496925] d approximately  10 to 30 minutes after 
albuterol/salbutamol administration.
9.1.2. SGRQ-C
The St George’s Respi[INVESTIGATOR_6015] -Chronic Obstructive Pulmonary  Disease 
specific (SGRQ -C) will be completed by  [CONTACT_496968] (Visit 2), Day 28
(Visit3),and Day 84 (Visit 4) .  When the SGRQ -C and the COPD Assessment Test 
(CAT) are collected at the same visit, the CAT should be collected prior to the SGRQ -C.
The SGRQ- C [Meguro, 2007] is a disease -specific questionnaire designed t o measure the 
impact of respi[INVESTIGATOR_496926] a COPD participant ’s HRQoL.  As well 
as producing an overall summary  score, scores for the individual domains of sy mptoms, 
activity and impacts are also produced .  It has been used in studies of COPD participants
and has been translated and validated for use in most major languages.  The SGRQ -C is  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
63derived from the original SGRQ, and produces scores equivalent to the SGRQ instrument 
[Meguro, 2007].  
9.1.3. COPD A ssessment Test (CAT)
The CAT will be completed by  [CONTACT_496969] (Visit 1), Randomisation (Visit 
2), Day 28 (Visit 3), and Day 84 (Visit 4).  CAT should be collected prior to SGRQ -C 
when collected at the same visit.
The COPD Assessment Test [Jones, 2009; Jones, 2012] is a validated, short and simple 
patient completed questionnaire which has been developed for use in routine clinical 
practice to measure the health status of patients with COPD. The CAT is an 8- item 
questionnaire suitable for completion by [CONTACT_453569].  When 
completing the questionnaire, participants rate their experience on a 6 -point scale, 
ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of [ADDRESS_638800].
9.1.4. COPD Exacerbations
COPD exacerbation data will be collected from the start of the randomised double blind 
treatment period (Visit 2) until the safety  follow up contact [CONTACT_293778] 6. Participants will 
complete a paper M edical Problems worksheet to record medical problems experienced 
during the stud y. This paper worksheet must be reviewed b y the Investigator (or 
designee) at each visit to the study  site to assist in the identification of new COPD 
exacerbations.  
Every effort should be made to conduct a chest x- ray within 48 hours of identification of 
a moderate or severe exacerbation. 
All COPD exacerbations will be recorded on theexacerbation page of the eCRF. 
Details on COPD Exacerbation I dentification, Categorizatio n and Treatment Guidelines 
are provided in Appendix 5 .
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 6
The Investigator and any designees are responsible for detecting, documenting, and
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  treatment or the study ,
or that caused the participant to discontinue the study  treatment or withdraw f rom the 
study(see Section 8).  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
649.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
AnySAEs assessed as related to study  participation (e.g., study  treatment , 
protocol-mandated procedures, or change in existing the rapy) or related to a 
[COMPANY_004] product will be recorded from the time a participant consents to participate 
in the study up to and including the safet y follow-up contact [CONTACT_293778] 6 .
All AEswill be collected from the start ofstudy treatment (Visit 2) until th e 
safety follow-up contact [CONTACT_496970] (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the eCRF not the AE section. 
All SAEswill be recorded and reported to the sponsor or designee immediately  
and under no circumstance should this exceed 24 hours, as indicated in
Appendix 6.The Investigator will submit any  updated SAE data to the sponsor 
or designee within 24 hours of it being available. 
Investigator s are not obligated to activel y seek AEs or SAEs in former study  
participant s. However, if the Investigator learns of any  SAE, includi ng a death, 
at any time after a participant has been discharged from the study , and he/she 
considers the event to be reasonabl y related to the study  treatment or study  
participation, the Investigator must promptl y notify the sponsor or designee .
The method of recording, evaluating, and assessing causality  of AEs and SAEs
and the procedures for completing and transmitting SAE reports are provided in
Appendix 6.
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias wh en detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence. 
Participants will be issued with a paper Medical Problems worksheet to record an y 
medical problems experie nced during the stud y. This paper worksheet will be used to 
assist participant recall in discussions with the Investigator (or designee), for site staff to 
then enter as appropriate in the eCRF. 
9.2.3. Follow-up of AEs and SA Es
After the initial AE/SAE report, t he Investigatoris required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs will be followed until the event is 
resolved, stabilized, otherwiseexplained, or the participant is lost to follow -up (as 
defined in Section 8.3). Further information on follow -up procedures is given in
Appendix 6. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
659.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_496971] a SAE is essential so 
that legal obli gations and ethical responsibilities towards the safet y of 
participant s and the safety  of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify both the local regulatory  
authority and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics C ommittees (I EC), and 
Investigator s.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy  and forwarded to Investigator s as necessary .
An Investigatorwho receives an Investigator safety report describing a SAE or 
other specific safet y information eg, summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator ’s Brochure and 
will notify  the IRB/IEC, if appr opriate according to local requirements.
9.2.5. Cardiovascular and Death Events
For any cardiovascular events detailed in Appendix 6and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV e CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms.The CV information should be recorded in the specific cardiovascular section of 
the eCRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
9.2.6. Disease -Related Outcomes –COPD exacerbations
COPD exacerbations are an expected disease- related outcome.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
669.2.7. COPD exacerbations should not be recorded as an adverse 
event, unless they  meet the definition of an SA E (Appendix 
6).Pneumonia
All suspected pneumonias will require confirmation as defined b y the presence of new 
infiltrate(s) on chest x -ray AND at least 2 of the following signs and s ymptoms: 
Increased cough 
Increased sputum purulence (colour) or production 
Auscultatory  findings of adventitious sounds ( e.g.egophony, bronchial breath 
sounds, rales, etc.)
Dyspnoea or tach ypnea
Fever (oral temperature >37.5 °C)
Elevated white blood cel ls (WBC)(>10,000/mm3or >15% immature forms)
Hypoxemia (HbO 2saturation <88 % or at least 2 % lower than baseline value)
All pneumonias must be captured on the AE/SAE page of the eCRF and on the 
pneumonia page of the eCRF.
The Investigator s and site sta ff should remain vigilant for the possible development of 
pneumonia in participants with COPD as the clinical features of such infections overlap 
with the sy mptoms of COPD exacerbations. Risk factors for pneumonia in participants
with COPD receiving FF/VIincludedcurrent smokers, participants with a history  of prior 
pneumonia, participant s with a body  mass index <25kg/m2and participants with an FEV 1
<50% predicted.  For all suspected cases of pneumonia, Investigator s are strongly 
encouraged to confirm th e diagnosis (this includes obtaining a chest x -ray) and to initiate 
appropriate therap y as promptly  as possible. All diagnoses of pneumonia 
(radiographicall y confirmed or unconfirmed) must be reported as an AE or SAE (if 
applicable).
Note: Pulse oximetry should be measured at any time a moderate or severe exacerbation 
is reported or pneumonia is suspected and recorded in the source documents and on the 
pneumonia page of the eCRF if applicable.
9.2.8. Sentinel Events
A Sentinel Event is a [COMPANY_004]- defined SAE that is not necessaril y drug-related but has been 
associated historicall y with adverse reactions for other drugs and is therefo re worthy  of 
heightened pharmacovigilance. Medical monitor review of all SAEs for possible Sentinel 
Events is mandated at [COMPANY_004].  The medica l monitor may  request additional clinical 
information on an urgent basis if a possible Sentinel Event is identified on SAE review. 
The current [COMPANY_004] -defined Sentinel Events are listed below:
Acquired Long QT Sy ndrome
Agranulocy tosis/Severe Neutropenia  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
67Anaphylaxis & Anaph ylactoid Reactions 
Hepatotoxicity
Acute Renal Failure
Seizure
Stevens Johnson S yndrome/Toxic Epi[INVESTIGATOR_19342]
9.2.9. Pregnancy
Details of all pregnancies in female participants will be collected after the start of 
study treatment and until the safet y follow-up contact/visit.
If a pregnancy  is reported, the Investigator should inform GS Kwithin 24 hoursof
learning of the pregnancy  and should follow the procedures outlined in Appendix 3.
Abnormal pregnancy  outcomes (eg, spo ntaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.2.10. Medical Device Incidents (Including Malfunctions)
Medical devices (spacers/holding chambers) are being provided for use in this study .In 
order to fulf ilregulatory  reporting obligations worldwide, the Investigator is responsible 
for the detection and documentation of events meeting the definitions of incident or 
malfunction that occur during the stud y with such devices. 
The definition of a Medical Devi ce Incident can be found in Appendix 7
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow th e processes 
outlined in Section 9.2and Appendix 6of the protocol. 
[IP_ADDRESS]. Time Period for Detecting Medical Device Incidents
Medical device incidents or malfunctions of the device that result in an incident 
will be detected, documented, and reported during all periods of the study  in 
which the medical device is used. 
If the Investigator learns of any  incident at an y time after a participant has been 
discharged from the study, and such incident is considered reasonabl y related to 
a medical devi ce provided for the study , the Investigator will promptl y notify 
the Sponsor.
The method of documenting Medical Device In cidents is provided in Appendix
7.
[IP_ADDRESS]. Follow-up of Medical Device Incidents
All medical device incidents involving an AE will be followed and reported in 
the same manner as other AE s(see Section 9.2).This applies to all participants,
including those who discontinue study  treatment or the study . 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
68The Investigator is responsible for ensuring that follow -up includes an y 
supplemental investigations as indicated to elucidate the na ture and/or causality  
of the incident.
New or updated information will be recorded on the originally  completed form 
with all changes signed and dated b y the Investigator .
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents to Sponsor
Medical device incidents will be reported to the sponsor within 24 hours after 
the Investigator determines that the event meets the protocol definition of a 
medical device incident.
The Medical Device Incident Report Form will be sent to the sponsor 
electronically .
The same individual will be the contact [CONTACT_496972].
[IP_ADDRESS]. Regulatory  Reporting Requirements for Medical Device Incidents
The Investigator will promptly  report all incidents occurring with any  medical 
device provided for use in the study  in order for the sponsor to fulfil the legal 
responsibility  to notify appropriate regulatory  authorities and other entities about 
certain safet y information relating to medical devices being used in clinical 
studies.
The Investigator , or responsible person according to local requirements (eg, the 
head of the medical institution), will comply  with the applicable local regulatory  
requirements relating to the reporting of incidents to the I RB/IEC.
9.3. Treatment of Overdose
An overdose is defined as a dose greater than the total doses described above which 
results in clinical signs and sy mptoms.  These should be recorded by  [CONTACT_417509]/SAE eCRF pages.  In the event of an overdose of study  treatment, the Investigator
should use clinical judgment in treatingthe overdose and contact [CONTACT_417510].
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management. The Investigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, pre cautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may include, but not be limited to, the IB or equivalent document provided by  [CONTACT_23983].
9.4. Safety Assessments
Planned time points for all safety  assessments are provided in the SoA (Section 2). 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
699.4.1. Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
Skin, Cardiovascular , Respi[INVESTIGATOR_696] , Gastrointestinal an d Neurological systems.
Height,weight will also be measured and recorded.
Investigator s should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
Vital signs will be performed at the time points specified in the SoA table 
(Section 2) prior to conducting spi[INVESTIGATOR_496927] .
Blood pressure (systolic and diastolic) and pulse measurements will be assessed 
in the sitting position after approximately  [ADDRESS_638801].
A single set of values will be collected and recorded in the source 
documentation and eCRF. 
9.4.3. Electrocardiograms
A single 12 -lead ECG and rhy thm strip will be recorded after measurement of 
vital signs and prior tospi[INVESTIGATOR_038] .Recordings will be made at the time -points 
defined in the SoA table (Section 2). All ECG measurements will be made with 
the participant in a supi[INVESTIGATOR_496928]  5 minutes before each reading.
For participant s who meet the QTc, protocol defined stoppi[INVESTIGATOR_3418], triplicate 
ECGs (over a brief period of time) should be performed ( Section 8.1.1).
The Investigator , a designated sub -Investigator or other appropriatel y trained
site personnel will be responsible for performing each [ADDRESS_638802] provide his/her dated signature [CONTACT_238540], 
attesting to the authenticity  of the ECG machine interpretation.
9.4.4. Clinical Safety Laboratory  Assessment s
Refer toAppendix 8for the list of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency . 
The Investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the eCRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the Investigator
to be more severe than expected for the p articipant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during parti cipation in the study  or within [ADDRESS_638803] dose of study  
treatment should be repeated until the values return to normal or baseline or are  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
70no longer considered significantly  abnormal by  [CONTACT_496973]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the Investigator , the etiology  should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 8,must be 
conducted in accordance with the laboratory  manual and the SoA.
9.5. Pharmacokinetic s
Pharmacokinetic parameters are not evaluated in this study .
9.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
9.7. Genetics
Information regarding genetic/ pharmacogenetic (PGx) research is included in
Appendix 9.The IEC/IRB and, where required, the applicable regulatory  agency must 
approve the PGx and genetic assessments before these can be conducted.  The 
approval(s) must be in writing and will clearl y specify approval of the PGx and genetic 
assessments (i.e., approval of Appendix 9).
In some cases, approval of the PGx and genetic assessments can occur after approval is 
obtained for the rest of the study .  If so, then the written approval will clearly  indicate 
approval of the PGx and genetic assessments is being deferred and the study , except for 
PGx and genetic assessments, can be initiated.  When PGx and genetic assessments will 
not be approved, then the approval for the rest of the study  will clearl y indicate this and 
therefore, PGx and genetic assessments will not be conducted.
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics parameters are not evaluated in this 
study.
9.10. Smoking Cessation Counselling
During Visits 1 and 4, or Study  Discontinuation, participants will be given smoking 
cessation counselling.  This will include advice regarding the following:
the health effects that smoking may  cause
the health benefits that may  result with smoking cessation 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
71discuss anti -smoking strategies that primary  care physicians may  be able to 
provide if participants do not feel capable of discontinuing smoking
participants may  discontinue smoking at an y time during the stud y and will not 
have to be wi thdrawn from the study  if they do so.
The specific information to be discussed with each participant is provided in the SRM.
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
The primary  objective of this study  is to compare single inhaler triple therapy  
(FF/UMEC/VI) withtiotropi[INVESTIGATOR_496929] s ymptomsas measured b y CAT 10.The primary  endpoint is 
trough FEV ₁at Week 24 (Day  85). The primary  analysis is the comparison of this 
endpoint between FF/UMEC/VI  and tiotropi[INVESTIGATOR_1890].   
The null hy pothesis is that there is no difference between treatment groups.
H0: T1 – T2 = 0
The alternative hy pothesis is there is a diffe rence between treatment groups.
H1: T1 – T2 0
Where T 1and T2are the treatment means for FF/UMEC/VI and tiotropi[INVESTIGATOR_1890] , respectivel y.
10.2. Sample Size Determination
Sample size calculation is based on the primary  endpoint of trough FEV 1 at Week 12 
(Day 85)and assumes 90 % power, a two- sided 1% significance level, an estimate of 
residual standard deviation of 240 mL (based on mixed model repeated measures 
[MMRM] analyses of closed triple Phase IIb study CTT116853 in COPD participant s) 
and a treatment difference of 70mL.Under these assumptions, in total 702 evaluable 
participant s(351 pertreatment group) will be required.
It is estimated that approximately  10% of participants will withdraw during the treatment 
period without providing a Day 85 trough assessme ntand approximately  8% of 
participants will drop out from the4 week run-in (including those not meeting 
randomisation criteria). Therefore approximately  [ADDRESS_638804] 780 participants randomised. 
10.3. Populations for A nalyses
For purposes of analy sis, the following populations are defined: 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638805] Enrolled (ASE)All participants for whom a record exists in the study database, 
including screen failures and any participant who wa s not 
screened but experienced an SAE between the date of informed 
consent and the planned date of the Screening visit.
Intent -toTreat
(ITT)All randomised participants, excluding those who were 
randomised in error. A participant who is recorded as a scr een 
or run -in failure and also randomised will be considered to be 
randomised in error. Any other participant who receives a 
randomisation number will be considered to have been 
randomised .
Displays will be based on the treatment to which the participant
was randomised .
10.4. Statistical A nalyses
10.4.1. Efficacy  Analyses
Efficacy analyses will be based on the ITT Population using only  data collected on -
treatment, unless otherwise specified.
Endpoint Statistical Analysis Methods
PrimaryThe primary endpoint of trough FEV 1 onDay 85 will be analysed for the ITT
Population using a mixed model repeated measures (MMRM) analysis, including 
trough FEV 1 recorded at each of visits, Day 28, Day 84 and Day 85. The model 
will include covariates of baseline FEV 1, visit, geographic al region , treatment and 
visit by [CONTACT_420780]. A visit by [CONTACT_496974]. The 
variance -covariance matrix will be assumed unstructured.
Estimated differences between FF/UMEC/VI and tiotropi[INVESTIGATOR_496930] 95 % confidence intervals (CIs) for the difference and p- values.
A “tippi[INVESTIGATOR_11300]” sensitivity analysis of trough FEV1 on Day [ADDRESS_638806] in participant s who 
discontinue study treatment . Assumptions will include scenarios where 
participant s who discontinue FF/UMEC/VI have a lower treatmen t effect than 
those who discontinue TIO. The analysis results will be used to explore the 
conditions under which the conclusion of superiority no longer holds.
SecondarySecondary endpoint change from baseline in trough FEV 1on Day 28 and Day 
84will b e part of the primary endpoint analysis (MMRM). 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
73Endpoint Statistical Analysis Methods
Secondary endpoint change from baseline in SGRQ total score at Week 4 (Day 
28) and Week 12(Day 84) will be analysed for the ITT Population using MMRM 
analysis, including covariates of baseline, geographical region ,treatment and visit 
by [CONTACT_420780]. A visit by [CONTACT_496975]. The variance -
covariance matrix will be assumed unstructured. Estimated differences between 
FF/UMEC/VI and tiotropi[INVESTIGATOR_496931] 95% CI for the 
difference and p -value.
OtherWill be described in the reporting and analysis plan .
10.4.2. Safety Analyses
All safety analyses will be performed on the ITTPopulation. 
Endpoint Statistical Analysis Methods
PrimaryThere is no primary safety analysis.
SecondaryThe following safety endpoints will be analysed descriptively by [CONTACT_1570]:
Incidence of adverse events
Incidence of adverse events of special interest (AE SI)  
Vital signs
Details will be described in the reporting and analysis plan
Adverse events (AEs) will be coded using the standard [COMPANY_004] dictionary , Medical 
Dictionary  for Regulatory  Activities (MedDRA), and grouped by [CONTACT_6764]. The 
number and percentage of participants experiencing at least one AE of any type, AEs 
within each body system and AEs within each preferred term will be presented for each 
treatment group. Separate summaries will be provided for all AEs, drug related AEs, fatal 
AEs, non-fatal SAEs, adverse events of special interest (AESIs) and AEs leading to 
withdrawal. Deaths and SAEs, if applicable, will be documented in case narrative format.
10.4.3. Other Analyses
Full details of the analyses to be performed on the primary and other efficacy endpoints 
will be given in the Reporting and Anal ysis Plan (RAP).
10.4.4. Interim A nalyses
No interim anal ysis is planned for this study . 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10328].4.5. Exploratory  Analyses
These exploratory  analyses may be provided in a separate RAP. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10329]. REFERENCES
Aaron SD, Vandemheen KL , Fergusson D, Maltais F, Bourbeau J, Goldstein R,  et al. 
Tiotropi[INVESTIGATOR_96867], Salmeterol, or Fluticasone –Salmeterol for 
Treatment of Chronic Obstructive Pulmonary  Disease A Randomized Trial. Ann Intern 
Med2007;146:545-555.
Cazzola M , Andò F, Sa ntus P, Ruggeri P, Di Marco F, Sanduzzi A, et al.  A pi[INVESTIGATOR_496932]/salmeterol and tiotropi[INVESTIGATOR_496933]-to-very severe COPD. Pul Pharm Ther 2007; 
20:556–561.
Celli BR, MacNee W , ATS/ERS Task Force . Standards for the diagnosis and treatment of 
patients with COPD: A summary  of the ATS/ERS position paper.  Eur Respir J 2004; 23: 
932-946.
Christensson C, Thoren A, L indberg B. Safet y of inhaled budesonide: clinical 
manifestations of sy stemic corticosteroid-related adverse effects. Drug Safety. 
2008;31:965 -988.
Crim C, Calverley  PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al.  Pneumonia 
risk in COPD patients receiving inhaled corticosteroids alone or in combina tion: TORCH 
study results. EUR Respi[INVESTIGATOR_3694] J 2009;34:641 -647.
De Bisschop MB, Bellou A. Anaph ylaxis. Curr Opin Crit Care. 2012;18:308-317.
Dransfield MT, Bailey  W, Crater G , Emmett A, O'Dell DM, Yawn B . Disease severit y 
and symptoms among subjects receiving mo notherapy  for COPD. Prim Care Resp J 
2011; 20): 46 -53.
Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al.  Once -
daily inhaled fluticasone furoate and vilanterol versus vilanterol only  for prevention of 
exacerbations of COPD: two r eplicate double -blind, parallel -group, randomised 
controlled trials. Lancet Respir Med 2013;1:210 -223.
Global Strategy for the Diagnosis, Management and Prevention of COPD , Global 
Initiative for Chronic Obstructive L ung Disease (GOLD) 2017. Available from:
heep://www.goldcopd.org/.
Global Strategy for the Diagnosis, Management and Prevention of COPD , Global 
Initiative for Chronic Obstructive L ung Disease (GOLD) 2013. Available from: 
http://www.goldcopd.org/.
GOLD. Global Initiative for Chronic Obstructive Lung Disease (Updated 2011). 
http://www.copdgold.org.
Hanania HA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
(Benefits of adding fluticasone propi[INVESTIGATOR_16847]/salmeterol to tiotropi[INVESTIGATOR_496934]. Resp Med 2012; 106: 91-101. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638807] (CAT) Eur Respir J 2009 ;34:648-654 
Jones PW, Harding G, Wiklund I , Berry P, Tabberer M, Yu R, Leid y N. ‘Tests of the 
Responsiveness of the Ch ronic Obstructive Pulmonary  Disease (COPD) Assessment Test 
(CAT) Following Acute Exacerbation and Pulmonary  Rehabilitation. Chest 2012;142:
134-140
JungKS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, et al. Comparison of tiotropi[INVESTIGATOR_496935]/salmeterol with tiotropi[INVESTIGATOR_496936]: A randomized 
controlled study . Resp Med 2012; 106: 382-[ADDRESS_638808]. 2011;139:648-657.
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL 
Trial: Once-Daily Triple Therapy in Patients with Chronic Obstructive Pulmonary 
Disease. Am J Respir Crit Care Med 2017;10.1164/rccm.201703- 0449OC. [Epub ahead 
of print]
Meguro M, Barley EA, Spencer S, Jones PW. Developm ent and validation of an 
improved COPD-Specific Version of the St. George Respi[INVESTIGATOR_21606]. Chest
2007;132:456-463.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. 
Standardisation of spi[INVESTIGATOR_038] . Eur Respir J. 2005;26:31 9-338.
Niggemann B, Bey er K. Factors augmenting allergic reactions. Allergy 2014;69:1582 -
1587.
Packe GE, Cay ton RM, Mashhoudi N. Nebulised ipratropi[INVESTIGATOR_496937] -angle glaucoma. Lancet1984;2:691.
Quanjer P, Stanojevic S, Cole T, Baur X, Hall G, Culver, BH, et al.Multi-ethnic 
reference values for spi[INVESTIGATOR_14436] 3-95- yr age range: The global lung function 2012 
equations. Eur Respi J 2012;40:1324-1343.
Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ.  Effect of 
budesonide/formorterol pMDI  on COPD exacerbations: A double -blind, randomized 
study. Respir Med 2012;106:257-268.
Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy  and safet y of 
umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary  
disease: results of two randomized studies. Respir Med . 2015; 109: 1155- 1163.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et alA 4-year Trial of 
Tiotropi[INVESTIGATOR_496938]. N Engl J Med 2008;359:1543-
1554. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
77Weldon D. The effects of corticosteroids on bone growth and bone density. Ann. Allergy 
Asthma Immunol. 2009;103:3-11.
Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T,et al.
Efficacy and Tolerability  of Budesoni de/Formoterol Added to Tiotropi[INVESTIGATOR_496939]. Am J Respir Crit Care Med2009;
180:741–750.
Wolters Kluwer's Source Lx Database Hierarchical Regimen Analysis (HRA) 
Application SLED Report With Filtering On Patients Aged 18+ With COPD Only. Data 
from February  [ADDRESS_638809] KE, Bushnell G, Shukla A, Muellerova H, Davis KJ. Factors Associated with 
Time to Triple Therap y in Newly Diagnosed COPD Patients in the [LOCATION_006] General Practice 
Research Database. (2013) 29th I nternational Conference on Pharmacoepi[INVESTIGATOR_496940], Montreal, Canada (August 25-28, 2013).  Abstract 62. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10330]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbreviations
AE Adverse Event
AESI Adverse Event of Sp ecial Interest
AF Atrial Fibrillation
ALT Alanine Transaminase
ASE All Subjects Enrolled
AST Aspartate Transaminase
ATS American Thoracic Society
BfS Federal Office for Radiation Protection
BMI Body Mass Index
BPM Beats per minute
BUD Budesonide
BUN Blood Urea Nitrogen
CAT COPD Assessment Test
CI Confidence Interval
CIOMS Council for International Organizations of Medical Sciences
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
CPRD Clinical Prac tice Research Database
CT Computerized Tomography
CV Cardiovascular
DNA Deoxyribonucleic acid
ECG Electrocardiogram
eCRF Electronic Case Report Form
EOS End of study
EXACT-RS Exacerbations and Chronic Pulmonary  Disease –
Respi[INVESTIGATOR_496941]1 Forced expi[INVESTIGATOR_4034] [ADDRESS_638810] 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
79HIV Human Immunodefi ciency Virus
HPA Hypothalamic -Pi[INVESTIGATOR_2117]-Adrenal
HPLC High-Performance Liquid C hromatograph y
HRQoL Health related quality  of life
HRT Hormone Replacement Therap y
IB Investigator ’s Brochure
ICF Informed Consent Form
ICH International Conference on Har monization
ICS Inhaled Corticosteroids
IEC Independent Ethics Committee
INR International Normalized R atio
IP Investigational Product
IRB Institutional Review Board
IWRS Interactive Web Response Sy stem
ITT Intent-to-Treat
IUD Intrauterine D evice
IUS Intrauterine Hormone -ReleasingSystem
Kg/m2Kilograms per meter squared
LABA Long-Acting Beta-[ADDRESS_638811] Infection
LTOT Long-term oxygen therapy
MACE Major Adverse Cardiac Event
MAOI Monoamine Oxidase I nhibitors
MedDRA Medicinal Dictionary  for Regulatory  Activities
mcg Microgram
MCHC Mean Corpuscular Hemoglobin Concentration
MCV Mean Corpuscular Volume
MDI Metered Dose Inhaler
min Minute
mL Milliliter
mMRC Modified Clinica l Research Council
MMRM Mixed-Model Repeated Measures
mPP Modified Per Protocol
MSDS Material Safet y Data Sheet
msec Millisecond
NA Not Applicable
NYHA [LOCATION_001] Heart Association
PDE4 Phosphodiestrase 4 inhibitor
PGx Pharmacogenetic
QTc QT interva l corrected for heart rate
QTcB QT interval corrected for heart rate b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Fridericia’s formula
RAP Reporting and Anal ysis Plan
RBC Red Blood Cell
RNA Ribonucleic acid 2019N398531_00
2017N323364_01 CONFIDENTIA L
[ADDRESS_638812]. George’s Respi[INVESTIGATOR_496942]-bearing potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_496976][INVESTIGATOR_496943] 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10331].2. Appendix 2: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be submitted to an I RB/IEC by  
[CONTACT_496977] b y the IRB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study  Participantss. 
The Investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently  in accordance with the requirements, policies, 
and procedures e stablished by  [CONTACT_1201]/EC
Notifying the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations( CFR), ICH guidelines, 
the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations
Financial Disclosure
Investigators and sub- Investigator s will provide the sponsor with sufficient, accurate 
financialinformation as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigator s are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The Investigator or his/her representative will explain the nature of the study  to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study .  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
82Participants must be informed that their participation is voluntary . Participants
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_638813] (HIPAA) 
requirements, where applicable, and the IRB/IEC or study  centre. 
The medical record must include a statement that written informed consent was 
obtained before th e participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their par ticipation in the study . 
A copy of the ICF(s) must be provided to the participant or the participant ’s 
legally authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a uniq ue identifier by  [CONTACT_456]. Any  participant
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant
identifiable will not be transferred. 
The participantmust be informed that his/her personal study -related data will be 
used by [CONTACT_10999]. The level of 
disclosure must also be explained to the participant . 
The participant must be informed that his/her medic al records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
Publication Policy
The results of this study  may be published or presented at scientific meetings. If 
this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The spons or will comply  with the requirements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generally support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating Investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be determined by  [CONTACT_43217]. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
83Dissemination of Clinical Stud y Data
Where required b y applicab le regulatory  requirements, an Investigator signatory 
will be identified for the approval of t he Clinical Study  Report.  The Investigator
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity  to review the complete study  results at a 
[COMPANY_004] site or other mutually -agreeable location.
[COMPANY_004] will also provide the Investigator with the full summa ry of the stud y 
results.  The Investigator is encouraged to share the summar y results with the 
study participants, as appropriate.
[COMPANY_004] will provide the Investigator with the randomisation codes for their site 
only after completion of the full statistical anal ysis.
The procedures and timing for public disclosure of the results summ ary and for 
development of a manuscript for publication will be in accordance with [COMPANY_004] 
Policy.
A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.
Data Quality  Assurance
All participant data relating to the stud y will be recorded on eCRF unless 
transmitted to the sp onsor or designee electronically  (eg, laboratory  data). The 
Investigator is responsible for verify ing that data entries are accurate and correct 
by [CONTACT_42507]. 
The Investigator must maintain accurate documentation (source data) that 
supports the information entered in the eCRF. 
The Investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study monitors will perform ongoing source data verification to confirm that 
dataentered into the eCRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participant s 
are being protected; and that the study is being conducted in accordance with the 
currently approve d protocol and any  other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by  [CONTACT_13177] 25 years from the issue of the fi nal 
Clinical Study  Report / equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroyed during the retention period without the written approval of the 
sponsor. No records may be tran sferred to another location or part y without 
written notification to the sponsor.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
84Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at t he 
Investigator ’s site.
Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discre pancies must be explained. 
The Investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be 
available.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any 
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The Investigator may initiate study -site closure at any  time, prov ided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a study site by [CONTACT_18484] I nvestigator may include 
but are not limited to:
Failure of the Investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the S ponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by[CONTACT_737]
Discontinuation of further study  treatment development 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10332].3. Appendix3: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below)
Women in the following cate gories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of Participants’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HR T and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopaus al status before study  enrollment.
Contraception Guidance
Female Participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in
Table 5.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
86Table 5 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1 % per year when used consistently and correctly. 
Combined (e strogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulationb
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation
injectable 
Highly Effective Methods Th at Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized pa rtner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.) 
Sexual ab stinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and 
the preferred and usual lifestyle of the Participants.)
NOTES: 
a. Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for Participantss in clinical studies. 
b. Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of 
the contraceptive method. In this case two highly effective methods of contr aception should be utilized during the 
treatment period .
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highly sensitive urinepregnancy  test  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
87Additional pregnancy testing should be performed during the treatment period (see 
SoA)and whenever a menstrual cy cle is missed or when pregnancy  is otherwise 
suspected 
Pregnancy  testing will be performed using the test kit provided by  [CONTACT_496978] s who become pregnant
Investigator will collect pregnancy  information on any  female participant , who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant 's pregnancy . 
Participants will be followed to determine the outcome of the pregnancy . The 
Investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] .Generally, follow-up will not be required for longer than 6 to 
8 weeks bey ond the estimated delivery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indicati on for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be report ed as 
such.  
Any SAE occurring as a result of a post -study pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_737] , will be reported to [COMPANY_004]
as described in Appendix 6. While the Investigatoris not obligated to actively  seek 
this information in former study  participant s, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study 
will immediately discontin ue study medication. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10333].4. Appendix 4: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase III-IVliver chemistry stoppi[INVESTIGATOR_496944] (in alignme nt with 
the FDA premarketing clinical liver safet y guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Phase III-IVliver chemistry stoppi[INVESTIGATOR_496945] - Liver Stoppi[INVESTIGATOR_496946] 
(ALT)-
absoluteALT  8xULN
ALT Increase ALT  5xULN but <8x ULN  persists for 2 weeks
ALT  3xULN but <5x ULN  persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN ( >35% direct bilirubin) 
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT  5xULN but <8x ULN and cannot be monitored weekly for 2 weeks
ALT  3xULN but <5x ULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN a ssociated with symptoms (new or worsening) believed to be 
related to  liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event eCRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries 
resol ve , stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge participant with Viral hepatitis serology4
Only in those with underlying chronic 
hepatitis B at study entry (identified by 
[CONTACT_23977] B surface antigen) 
quantitative hepatitis B DNA and hepatitis 
delta antibody5.
Blood sample for pharmacokinetic 
analysis, obtained within [ADDRESS_638814] dose6
Serum creatine phosphokinase and lactate 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
89study treatment unless allowed per protocol 
If restart/rechallenge not allowed per 
protocol , permanently discontinue study 
treatment and may c ontinue participant in the 
study for any protocol specified follow up 
assessments
MONITORING:
For bilirubin or INR criteria:
Repeat l iver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments with in  24 
hrs
Monitor participant s twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosph atase, bilirubin) and perform 
liver event follow up assessments within  24-
72 hrs 
Monitor participant s weekly until liver 
chemistries resolve, stabilize or return to 
within baselinedehydrogenase.
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential acetaminophen 
contribution to l iver injury in participant s 
with definite or likely acetaminophen use 
in the preceding week [James, 2009]). 
NOTE: not required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy t o evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy eCRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that partcipant if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Allevents of ALT  3xULN and bilirubin 2xULN (>35 % direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhos is); INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or te nderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)    2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
904. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody ;  Epstein- Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. If hepatitis delta antibody assay cannot be performed,, it can be replaced with a PCR of hepatitis D RNA viru s 
(where needed) [ Le Gal , 2005].
6. PK sample may not be required for participant s known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the 
participant ’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shippi[INVESTIGATOR_23915].  
Phase III-IVliver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  5xULN and <8xULN and
bilirubin <2x ULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT  3xULN and <5x ULN and
bilirubin < 2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeks.Notify the [COMPANY_004] medical monitor within 24 hours
of learning of the abnormality to discuss 
participant safety. 
Participant can continue study treatment  
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_33084], proceed as described above
If ALT decreases from ALT 5xULN and
<8xULN to ≥3xULN but <5x ULN, continue to 
monitor liver chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3x ULN and 
bilirubin <2x ULN, monitor participant s twice 
monthly until liver chemistries normalize or return 
to within baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et al. 
Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
Le GalF, GordienE,Affolabi D , Hanslik T,AllouiC, DényP, et al.  Quantification of 
Hepatitis Delta Virus RNA in Serum by  [CONTACT_31861] -Time PCR I ndicates Different 
Patterns of Virological Response to Interferon Therap y in Chronicall y Infected Patients .  
J Clin Microbiol. 2005 ;43:2363-2369. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10334].5. Appendix 5 : COPD Exacerbation Identification, 
Categorization and Treatment Guidelines
12.5.1. Guidelines for Identifying COPD Exacerbations
The following are s ymptoms used to ascertain an exacerbation of COPD:
Worsening of two or more of the following major sy mptoms for at least two consecutive 
days:
Dyspnoea
Sputum volume
Sputum purulence (color)
OR
Worsening of an y one major symptom together with any  one of the following minor 
symptoms for at least two consecutive day s:
Sore throat
Colds (nasal discharge and/or nasal congestion)
Fever (oral temperature >37.5 °C) without other cause
Increased cough
Increased wheeze
Participants who experience worsening COPD symptoms for greater than 24 hours 
should:
Contact [CONTACT_496979]/or research coordinator immediately , and 
report to the study  clinic as required
If the participant is unable to contact [CONTACT_23976] y Investigator and/or research 
coordinator, they  should contact [CONTACT_496980] (or other health care 
practitioner as required) and contact [CONTACT_496981]
If the participant seeks emergency /acute care for worsening respi[INVESTIGATOR_120340], he/she should requestthe caring Health Care Provider (HCP) to 
contact [CONTACT_496982].
Participant s with worsening respi[INVESTIGATOR_496947]:
A mild/moderate/severe exacerbation and/or pneumonia
OR
A Lower Respi[INVESTIGATOR_168002] (L RTI)
Background variability  of COPD
A non-respi[INVESTIGATOR_23910]
Other respi[INVESTIGATOR_23910] 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10335].5.2. COPD E xacerbation Severity
Each COPD exacerbation will be categorized based on severit y as follows:
Mild:  Worsening sy mptoms of COPD that are self -managed b y theparticipant .  
Mild exacerbations are not associated with the use of corticosteroids or 
antibiotics.
Moderate :  Worsening sy mptoms of COPD that require treatment with 
oral/systemiccorticosteroids and/or antibiotics.
Severe: Worsening s ymptoms of COPD that require treatment with in -patient 
hospi[INVESTIGATOR_059].
Every effort should be made to conduct a chest x-ray within 48 hours of 
identification of a moderate or severe exacerbation . 
Details of an exacerbation should be recorded in the exacerbation page of the eCRF. 
However, exacerbations should not be recorded in the AE section of the eCRF unless 
they meet the definition of an SAE. (Pneumonia must be recorded in the AE or SAE 
section of the eCRF a nd on the Pneumonia page of the eCRF.)
Use of antibiotics for the treatment of upper or lower respi[INVESTIGATOR_496948] a COPD exacerbation unless the participant experiences worsening 
symptoms of COPD which match the definition of an exacerbation as given above.
12.5.3. Treatment of COPD Exacerbations
All medications used for the treatment of exacerbations must be recorded in the source 
documents a nd the exacerbation page of the eCRF.  All sites should follow the protocol 
treatment guidelines (as outline dbelow), but an y medications deemed medically  
necessary  may be used to treat a COPD exacerbation. However, caution is advised in 
using a LABA or LA MA to treat a participant currently taking IP as these additional 
medications may  increase the risk of overdose. If necessary  the PI [INVESTIGATOR_496949]’ s study treatment temporarily  in order to treat the 
COPD exacerbat ion.
12.5.4. Guidelines for Treatment with Corticosteroids
If in the opi[INVESTIGATOR_689]/treating ph ysician the exacerbation is severe enough 
to warrant the need for oralor systemic corticosteroids (with or without antibiotics) the 
following guidelines sh ould be used.
The duration of treatment with oral/sy stemic corticosteroids should be 14 days (dose 
and type according to local practice) 
The duration of treatment with oral/sy stemic corticosteroids should not exceed 14 
days unless approval is given by  [CONTACT_107634]
Any course of oral/s ystemic corticosteroids started within 7 day s of finishing a 
previous course will be considered as treatment for a single exacerbation 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10336].5.5. Guidelines for Treatment with A ntibiotics
If there is evidence of respi[INVESTIGATOR_496950]:
The duration of treatment with antibiotics should be 7 to 14 day s (dose and ty pe 
according to local practice). If first line antibiotic treatment fails and additional 
antibiotics are used, the total duration of antibiotic treatment should not exceed 30 
days unless approval for participants to continue on study  treatment is given by  [CONTACT_496983]
Any course of antibiotics started within [ADDRESS_638815] day  (of at least 2 consecutive day s) of worsening s ymptoms.
The date of resolution should be based on when the Investigator and/or participant 
determines that the COPD sy mptoms have returned to pre -exacerbation levels or to a new 
baseline.  In determining this resolution date, consideration should be given to diary  
recorded s ymptoms and/or study  participant evaluation.
12.5.7. Guideline for assessing multiple mild exacerbations
Two mild exacerbations can be combined int o one, per the Investigator’s judgement, if a 
participant’s diary reveals that the two mild COPD exacerbations are separated by  [CONTACT_496984] s.
12.5.8. Guideline for assessing exacerbations that increase in severity
If an exacerbation st arts off as mild, but becomes moderate or severe or starts off as 
moderate and becomes severe, the exacerbation should be captured as one exacerbation 
and classified b y its highest level of severity. 2019N398531_00
2017N323364_01 CONFIDENTIA L
[PHONE_10337].6. Appendix 6: Adverse Events: Definitions and Procedures f or 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant , temporally  
associated with the use of a study  treatment, whether or not considered related to the 
study treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definitio n 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in th e 
medical and scientific judgment o f the Investigator (ie, not related to progression of 
underlying disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after study  treatment administration even 
though it may  have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical seque lae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported re gardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae result ing from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, "lack of 
efficacy" or "failure of expected pharmacological action" constitutes an AE or SAE. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
95Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associat ed with the underl ying disease, unless judged by  [CONTACT_13142] ’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant ’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it c annot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life-threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hypotheticall y might have caused death, if it were more se vere.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_496951]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d.Resultsin persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
96normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncompli cated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_268678]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, int ensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigator s will be required to fill out the specific CV event page of the eCRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrhythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascul ar events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
97Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, i t is the responsibility  of the Investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
The Investigator will then record all relevant AE/SAE information in the eCRF.
It is notacceptable for the Investigator to send photocopie s of the participant’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAEe CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].
The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The Investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299] , causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
everyday activities.
Severe: An event tha t prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The Investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The Investigator will use clinical judgment to determine t he relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
98administration will be considered and investigated.
The Investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
For each AE/SAE, the Investigator mustdocument in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  besituations in which an SAE has occurred and the Investigator has 
minimal information to include in the initial report to [COMPANY_004].However, it is very 
important that the Investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004].
The Investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when d etermining regulatory  
reporting requirements.
Follow -up of AE and SAE
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_496985]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in t he study or during a recognized follow -
up period, the Investigator will provide [COMPANY_004] with a cop y of any post-mortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The Investigator will submitany  updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
TheInvestigator or medically -qualified sub -Investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study participation (causalit y) within 72 hours of SAE  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
99entryinto the eCRF.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to the assigned SAE contact [CONTACT_107461].
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to t ransmit 
this information to the SAE contact.
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the Investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[ZIP_CODE].7. Appendix7: Medical Device Incidents: Definition and 
Procedures for Recording, Evaluating, Follow -up, and 
Reporting
Definition and Documentation of Medical Device Incidents
Definitions of a Medical Device Incident
The detection and documentation procedures describ ed in this protocol apply to all [COMPANY_004] 
medical devices provided for use in the stud y. 
Medical Device Incident Definition
A medical device incident is any  malfunction or deterioration in the characteristics 
and/or performance of a device as well as an y inadequacy in the labeling or the 
instructions for use which, directly or indirectl y, might lead to or might have led to 
the death of a participants /user/other person or to a serious deterioration in his/her 
state of health.
Not all incidents lead to death or serious deterioration in health. The nonoccurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
An incidentassociated with a device happened and
The incidentwas such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deterioration in state of health can include an y of the following:
Life-threatening illness
Permanent impairment of body  function or permanent damag e to body structure
Condition necessitating medical or surgical intervention to prevent one of the 
above 
Fetal distress, fetal death, or an y congenital abnormality  or birth defects 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
101Examples of incidents
A participant , user, caregiver, or healthcare professional is injured as a result of a 
medical device failure or its misuse.
A participant ’sstudy treatment is interrupted or compromised by  a medical device 
failure.
A misdiagnosis due to medical device failure leads to inappropriate treatment.
A participan t’shealth deteriorates due to medical device failure.
Documenting Medical Device Incidents
Medical Device Incident Documenting
Any medical device incident occurring during the study  will be documented in the 
participant ’s medical records, in accordancewith the Investigator ’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE 
eCRF page will be completed as described in Appendix 6.
The form will be completed as thoroughl y as possible and signed b y the Investigator
before transmittal to the [COMPANY_004].
It is very important that the Investigator provides his/her assessment of causality  
(relationship to the medical device provided b y [COMPANY_004])at the time of the initial report 
and describes an y corrective or remedial actions taken to prevent recurrence of the 
incident.
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of an incident. 
This includes any  amendment to the device design to prevent recurrence. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[ZIP_CODE].8. Appendix8: Clinical Laboratory  Tests
All protocol required laboratory  assessments (haematology , clinical chemistry  
and urinal ysis) must be conducted in accordance with the L aboratory  Manual, 
and Protocol SoA(Section 2).Laboratory requisition forms must be completed 
and samples must be clearly labelled with the participant number, protocol 
number, site/cen tre number, and visit date. Details for the preparation and 
shipment of samples will be provided b y the laboratory and are detailed in the 
Laboratory  Manual. Reference for all safet y parameters will be provided to the 
site by [CONTACT_90633].
All blood samples which will be taken pre -dose, will be sent to a central 
laboratory  for analysis (details provided in the Laboratory  Manual). Standard 
reference ranges will be used. 
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in participant management or 
are considered clinically  significant b y the Investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF. 
Refer to the Laboratory  Manual for appropriate processing and handling of 
samples to avoid duplicate and/or additional blood draws.
Protocol-specific requirements for inclusion or exclusion of participants are 
detailed in Section 6.1of the protocol.
Additional tests may  beperformed at any  time during the study  as determined 
necessary  by [CONTACT_399965] b y local regulations. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
103Table 6Protocol -Required Safety  Laboratory  Assessments
Laboratory 
Assess mentsParameters
Hematology Platelet Count RBC Indices:
Mean Corpuscular 
Volume (MCV )
Mean Corpuscular 
Hemoglobin ( MCH)WBC count with 
Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hemoglobin
Hematocrit
Clinical 
Chemistry1Blood Urea 
Nitrogen (BUN )Potassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic-
Oxaloacetic 
Transaminase
(SGOT)Total and direct 
bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic- Pyruvic 
Transaminase
(SGPT)Total Protein
Glucose 
[nonfasting]Calcium Alkaline 
phosphatase
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFollicle -stimulating hormone and estradiol (as needed in women of non-
childbearing potential only)
 Serum/urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)[ADDRESS_638816] be entered into the e CRF.
NOTES :
1. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver stoppi[INVESTIGATOR_43191] 8.1and Appendix 7All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin 2 × ULN (>35 % direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) >1.5, if INR 
measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis).
2. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_18039]/IEC. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[ZIP_CODE].9. Appendix9: Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant ’s response to therap y, susceptibility , 
severity and progression of disease. Variable response to therap y may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the dru g; disease etiology ; and/or molecular 
subtype of the disease being treated. Therefore, where local regulations and I RB/IEC 
allow, a 6 mL  bloodsample will be collected for DNA anal ysis.
DNA samples maybe used for research related to study treatment orCOPDand 
related diseases. They  may also be used to develop tests/assay s including diagnostic 
tests) related to study treatment or study  treatments of this drug class and indication.
Genetic research may  consist of the analy sis of one or more candidate genes 
(including but not limited to: PIK3CD, PIK3CA, IL10, CHRNA3 , CHRNA5 , DNAH5, 
SUMF1, and CELSR1) or the anal ysis of genetic markers throughout the genome [or 
analysis of the entire genome] (as appropriate)
The samples may  be analyzed as part of a multi- studyassessment of genetic factors 
involved in the response to study treatment or study treatments of this class. The 
results of genetic anal yses may be reported in the clinical study  report or in a 
separate study  summary .
In the event of DNA extraction failur e, a replacement genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained while research on study treatment (or study treatments 
of this class) or indication continues but no longer than [ADDRESS_638817] visit or other period as per local requirements.
Withdraw Process :  If a participant withdraws consent, the Investigator must 
complete the Genetic Sample Destruction Request Form, which will be provided to 
the site in the I nvestigator Site File.
Destruction Process :  After the specified storage period of [ADDRESS_638818] of chain of custod y is maintained.  A laboratory information 
management s ystem (LIMS) is used to track and identify samples for destruction. 2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[ZIP_CODE].10. Appendix 10: Country -specific requirements
There are currently  no country  specific requirements.  2019N398531_00
2017N323364_01 CONFIDENTIA L
207626
[ZIP_CODE].11. Appendix 11 : Protocol A mendment H istory
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC). 2019N398531_00